भारत का राजपत्र

The Gazette of India

असाधारण

EXTRAORDINARY

भाग II—खण्ड 3—उप-खण्ड (ii)

PART II—Section 3—Sub-section (ii)

प्राधिकार से प्रकाशित

PUBLISHED BY AUTHORITY

सं. 608] नई दिल्ली, वृहदस्पतिक, मार्च 10, 2016/फलघु 20, 1937

No. 608] NEW DELHI, THURSDAY, MARCH 10, 2016/PHALGUNA 20, 1937

स्वास्थ्य और परिवार कल्याण मंत्रालय

(स्वास्थ्य और परिवार कल्याण विभाग)

अधिसूचना

नई दिल्ली, 10 मार्च, 2016

का.आ. 705(४)—केन्द्रीय सरकार का यह समाधान हो गया है कि एसिक्लोफेनक + पेरासिटामोल + रेफ्राजोल की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन को बताता होने की संभावना है, जबकि उक्त औषधि के गुरूत्व के अनुकूल उपलब्ध है;

और इस विषय की केन्द्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केन्द्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विकिरण औषधि नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केन्द्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण को प्रतिपित करके विनिमय करना लोकप्रिय में आबादित और सामाजिक है;

अतः अब, केन्द्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रमाण नागरिक अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, एसिक्लोफेनक + पेरासिटामोल + रेफ्राजोल की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तकाल प्रभाव में प्रतिपित करती है।

[फ.सं. एक्स-11035/53/2014-डीएफज्यूजी]

कुंदन लाल शर्मा, संयुक्त सचिव
MINISTRY OF HEALTH AND FAMILY WELFARE
(Department of Health and Family Welfare)

NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 705(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Aceclofenac + Paracetamol + Rabeprazole is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Aceclofenac + Paracetamol + Rabeprazole with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 706(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Nimesulide + Diclofenac is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;
And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Nimesulide + Diclofenac** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 707(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Nimesulide + Cetirizine + Caffeine** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Nimesulide + Cetirizine + Caffeine** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 708(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Nimesulide + Tizanidine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Nimesulide + Tizanidine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 709(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Paracetamol + Cetirizine + Caffeine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Paracetamol + Cetirizine + Caffeine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION
New Delhi, 10th March, 2016

S.O. 710(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Diclofenac + Tramadol + Chlorzoxazone is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Diclofenac + Tramadol + Chlorzoxazone with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अधिसूचना
नई दिल्ली, 10 मार्च, 2016

कां.आ. 711(ब).—केंद्रीय सरकार का यह समाधान हो गया है कि डाइक्लोमाइन + पारासीटामोल + डोमपेरिडोन की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन के खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपलब्ध हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय आपत्ति नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण को प्रतिष्ठित करने वाली प्रणाली में आवश्यक और समीचीन हैं;

इत्यादि, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रयोगात्मक सामग्री अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रतिलिपि शक्तियों का प्रयोग करते हुए, डाइक्लोमाइन + पारासीटामोल + डोमपेरिडोन की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तक्तक प्रभाव से प्रतिष्ठित करती है।

[फा. सं. एक्स-11035/53/2014-डीएफएससी]

कुंदल लाल शर्मा, संयुक्त मंत्री

NOTIFICATION
New Delhi, 10th March, 2016

S.O. 711(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Dicyclomine + Paracetamol + Domperidone is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;
Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Dicyclomine + Paracetamol + Domperidone** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

**NOTIFICATION**

New Delhi, 10th March, 2016

S.O. 712(E).— Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Nimesulide + Paracetamol dispersible tablets** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Nimesulide + Paracetamol dispersible tablets** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
बिविधयुक्त

नई दिल्ली, 10 मार्च, 2016

का. आ. 713(ब).—केन्द्रीय सरकार का यह समाधान हो गया है कि पेरासिदिमोल + फिनाइफ्रील + कैफीन की नियत खुराक संयोजन औषधि के प्रयोग में मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपलब्ध है,

और इस विषय की केन्द्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केन्द्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई सिफारिशी औषधि नहीं है,

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केन्द्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विवेकाय विनिमय, विक्रय और चिकित्सा को प्रतिष्ठित करने और विनियमित करना लोकहित में आवश्यक और समितीय है,

अतः, जब, केन्द्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन सामग्री अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रतिप्रकाश का प्रयोग करते हुए, पेरासिदिमोल + फिनाइफ्रील + कैफीन की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विवेकाय विनिमय, विक्रय और चिकित्सा तत्काल प्राप्त से प्रतिष्ठित करती है।

[फ. नो. ए.सी.सी./11035/53/2014-डी.एफ.जी.सी]
कुंदल लाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, 10th March, 2016

S.O. 713(E).— Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Paracetamol + Phenytoin + Caffeine** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Paracetamol + Phenytoin + Caffeine** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

बिविधयुक्त

नई दिल्ली, 10 मार्च, 2016

का. आ. 714(ब).—केन्द्रीय सरकार का यह समाधान हो गया है कि डिएफ.जी.सी. + ट्रेमाइमोल + पेरासिदिमोल की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपलब्ध हैः

और इस विषय की केन्द्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केन्द्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई सिफारिशी औषधि नहीं हैः
AND Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Diclofenac + Tramadol + Paracetamol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, 10th March, 2016

S.O. 714(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Diclofenac + Tramadol + Paracetamol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Diclofenac + Tramadol + Paracetamol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

बाध्यूपजना

नई दिल्ली, 10 मार्च, 2016

का.आ. 715(ब).—केंद्रीय सरकार का यह समाधान हो गया है कि बाइक्लोफेन + प्रैसिटामोल + फ्लोरिजोक्सासिओन + फेमोटिडाइडन की नियत बुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुरूप उपलब्ध हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार की यह सिफारिश की है कि उक्त औषधि के बारे में यह चर्चा गया है कि इसका कोई चिकित्सीय अधिकार नहीं है;

और उक्त विशेषज्ञ समिति के सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विज्ञापन विनिमय, विज्ञापन और वितरण का वित्तीय करक्षण नियंत्रित करने लोकहित में आवश्यक और समीचीन है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति के सिफारिशों के आधार पर और औषधि और प्रसाधन सामग्री अधिनियम, 1940 (1940 का 23) की धारा 26क के अर्थात अधिनियम के प्रयोग करते हुए, बाइक्लोफेन + प्रैसिटामोल + फ्लोरिजोक्सासिओन + फेमोटिडाइडन की नियत बुराक संयोजन औषधि का मानव उपयोग के लिए विज्ञापन विनिमय, विज्ञापन और वितरण तत्काल प्रभाव से विनिमय करती है।

[फा. सं. एक्स-11035/53/2014-डीएफएसकी]
NOTIFICATION

New Delhi, 10th March, 2016

S.O. 715(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Diclofenac + Paracetamol + Chlorzoxazone + Famotidine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Diclofenac + Paracetamol + Chlorzoxazone + Famotidine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Naproxen + Paracetamol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 717(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Nimesulide + Serratiopeptidase is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Nimesulide + Serratiopeptidase with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
S.O. 718(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Paracetamol + Diclofenac + Famotidine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Paracetamol + Diclofenac + Famotidine with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
And whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Nimesulide + Pitofenone + Fenpiverinium + Benzyl Alcohol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Nimesulide + Pitofenone + Fenpiverinium + Benzyl Alcohol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 719(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Nimesulide + Pitofenone + Fenpiverinium + Benzyl Alcohol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Nimesulide + Pitofenone + Fenpiverinium + Benzyl Alcohol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 720(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Omeprazole + Paracetamol + Diclofenac is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Omeprazole + Paracetamol + Diclofenac with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 721(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Nimesulide + Paracetamol injection is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

New Delhi, the 10th March, 2016

K. L. SHARMA, Jt. Secy.
Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Nimesulide + Paracetamol injection** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

**NOTIFICATION**

New Delhi, the 10th March, 2016

S.O. 722(E).— Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Tamsulosin + Diclofenac** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;  

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;  

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;  

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Tamsulosin + Diclofenac** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 723(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Paracetamol + Phenylephrine + Chlorpheniramine + Dextromethorphan + Caffeine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Paracetamol + Phenylephrine + Chlorpheniramine + Dextromethorphan + Caffeine with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जाँच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय आवश्यकता हासिल नहीं है।

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण को प्रतिष्ठित करने विनिमयित करना लोकहित में आवश्यक और समीचीन है।

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन सामग्री अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, डाइक्लोफेनाइक + विक कार्नोसाइन की नियम बुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तक्तान प्राप्ति से प्रतिष्ठित करती है।

[फा. स. एक्स-11035/53/2014-डीएफसी]
कृष्ण लाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 724(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Diclofenac + Zinc Carnosine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Diclofenac + Zinc Carnosine with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

अभियुक्त

नई दिल्ली, 10 मार्च, 2016

का.आ. 725(उ)—केंद्रीय सरकार का यह समाधान हो गया है कि डाइक्लोफेनाइक + पेरासिटामोल + क्लोरफेनाइमोल ग्लेट + मेनोलिम ट्रायसिलिकेट की नियन्त्रण बुराक संयोजन औषधि के रूप में मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के मुक्तित्व अनुकूलन उपलब्ध है;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जाँच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय आवश्यकता नहीं है।

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण को प्रतिष्ठित करने विनिमयित करना लोकहित में आवश्यक और समीचीन है।

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन सामग्री अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, डाइक्लोफेनाइक + पेरासिटामोल
NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 725(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Diclofenac + Paracetamol + Chlorpheniramine Maleate + Magnesium Trisilicate is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

Now, therefore, on the basis of the recommendation of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Diclofenac Sodium + Paracetamol + Chlorpheniramine Maleate + Magnesium Trisilicate with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 726(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Paracetamol + Pseudoephedrine + Citrizine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;
And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Paracetamol + Pseudoephedrine + Cetirizine with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 727(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Phenylbutazone + Sodium Salicylate is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug Phenylbutazone + Sodium Salicylate with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 728(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Lornoxicam + Paracetamol + Trypsin is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Lornoxicam + Paracetamol + Trypsin with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विभेदकार्य विनिमय, विक्रय और वितरण को प्रतिपित करने विनिमय करना लोकतंत्र में आवश्यक और समीचीन है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन मामले अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, निमेन्स्लूअल + ब्रायक्लोइड + राटिटिडीन + डाइसिलोमाइन की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विभेदकार्य विनिमय, विक्रय और वितरण तक्ताल प्रभाव में प्रतिपित करती है।

[फा. सं. एक्स-11035/53/2014-डीएफक्वूसी]
कुदन लाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 729(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Paracetamol + Mefenamic Acid + Ranitidine + Dicyclomine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Paracetamol + Mefenamic Acid + Ranitidine + Dicyclomine with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

बधिष्यवाचन

नई दिल्ली, 10 मार्च, 2016

का.आ. 730(अ).—केंद्रीय सरकार का यह समाधान हो गया है कि निमेन्स्लूअल + ब्रायक्लोइड की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरुचिपूर्वक अनुच्छेद उपलब्ध हैं;

और इस विषय की केंद्रीय सरकार द्वारा निर्युक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विकृतिस्फूर्ती अंशिक्षण नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विभेदकार्य विनिमय, विक्रय और वितरण को प्रतिपित करके विनिमय करना लोकतंत्र में आवश्यक और समीचीन हैं;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन मामले अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, निमेन्स्लूअल + ब्रायक्लोइड की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विभेदकार्य विनिमय, विक्रय और वितरण तक्ताल प्रभाव में प्रतिपित करती है।

[फा. सं. एक्स-11035/53/2014-डीएफक्वूसी]
कुदन लाल शर्मा, संयुक्त सचिव
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 730(E).— Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Nimesulide + Dicyclomine** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Nimesulide + Dicyclomine** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अधिसूचना

नई दिल्ली, 10 मार्च, 2016

का.ञा. 731(ब).—केंद्रीय सरकार का यह समाधान हो गया है कि हेपारिन + डाइक्लोफेनक हे की नियात खुराक संयोजन औषधि के प्रयोग में मानव जीवन की खतरा होने की संभावना है, जबकि उक्त औषधि के मुक्तित अनुकूल उपयोग हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विचित्र सी औषधि नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयाय विनिमय, विक्रय और वितरण को प्रतिष्ठित करें विनियमित करना लोकहित में आवश्यक और सम्मिलक हैं;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन सामग्री अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, हेपारिन + डाइक्लोफेनक की नियात खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयाय विनिमय, विक्रय और वितरण तकनीक प्रभाव से प्रतिष्ठित करती है।

[फ. म. एक्स-11035/53/2014-डीएफसी]

कुंदन लाल शर्मा, समुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 731(E).— Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Heparin + Diclofenac** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;
And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Heparin + Diclofenac with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 732(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Glucosamine + Methyl Sulfonyl Methane + Vitamin D3 + Manganese + Boron + Copper + Zinc is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Glucosamine + Methyl Sulfonyl Methane + Vitamin D3 + Manganese + Boron + Copper + Zinc with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 733(E).— Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Paracetamol + Tapentadol** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **Paracetamol + Tapentadol** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Tranexamic Acid + Proanthocyanidin** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 734(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Tranexamic Acid + Proanthocyanidin** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Tranexamic Acid + Proanthocyanidin** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

विध्युदित

नई दिल्ली, 10 मार्च, 2016

का.आ. 735(ब).—केंद्रीय सरकार का यह समाधान अंतिम आदेश है कि **बेकोसीनिदम क्लोराइड + लिडोकेन** की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपयोग है।

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार की यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विचित्र साधन नहीं है।

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण को तत्काल प्रभाव से प्रतिष्ठित करती है।

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन सामग्री अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रतिलिपि ग्रहण करते हुए, **बेकोसीनिदम क्लोराइड + लिडोकेन** की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तत्काल प्रभाव से प्रतिष्ठित करती है।

[फ. सं. एयर 11035/53/2014-डीएफ्सीजी]
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 735(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Benzoxyonium Chloride + Lidocaine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Benzoxyonium Chloride + Lidocaine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अधिकृति

नई दिल्ली, 10 मार्च, 2016

का.आ. 736(ब).—केन्द्रीय सरकार का यह समाधान हो गया है कि लोरनोक्सिम + पेरासिदामोल + त्रामोल की नियमित खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपलब्ध हैं;

और इस विषय की केन्द्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केन्द्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय अधिकत हैं;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केन्द्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनियमण, विक्रय और वितरण को प्रतिष्ठित करके विनियमित करना लोकहित में आवश्यक और समीचीन हैं;

अतः, अब, केन्द्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन समीचीन अधिनियम, 1940 (1940 का 23) की धारा 26(क) द्वारा प्रकट शक्तियों का प्रयोग करते हुए, लोरनोक्सिम + पेरासिदामोल + त्रामोल की नियमित खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनियमण, विक्रय और वितरण तत्काल प्रभाव से प्रतिष्ठित करती है।

[फा. सं. एक्स-11035/53/2014-डीएफसी]

कुंदल लाल शर्मा, सचिव मंत्री

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 736(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Lornoxicam + Paracetamol + Tramadol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;
Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Lornoxicam + Paracetamol + Tramadol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 737(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Lornoxicam + Paracetamol + Serratopeptidase is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Lornoxicam + Paracetamol + Serratopeptidase with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
विचारपत्र

नई दिल्ली, 10 मार्च, 2016

का.व. 738(ब)—केन्द्रीय सरकार का यह समाधान हो गया है कि डाइक्लोफेनक + परेसिटामोल + मेनेसिक्यम ट्राइसिलिकेट की नियंत्रण खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपलब्ध हैं;

और इस विषय की केन्द्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केन्द्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विकित्सीय औषधि नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केन्द्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रृयार्थ विनिवेश, विक्रय और वितरण को प्रतिष्ठित करके विनिवेशित करना लोकहित में आवश्यक और समीचीन है;

अतः, जब, केन्द्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसादन मामला अधिनियम, 1940 (1940 का 23) की धारा 26(क) द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, डाइक्लोफेनक + परेसिटामोल + मेनेसिक्यम ट्राइसिलिकेट की नियंत्रण खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रृयार्थ विनिवेश, विक्रय और वितरण तत्काल प्रभाव से प्रतिष्ठित करती है।

[फा. सं. एक्स-11035/53/2014-दीएफसी]
कुंदन लाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 738(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Diclofenac + Paracetamol + Magnesium Trisilicate is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Diclofenac + Paracetamol + Magnesium Trisilicate with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

विचारपत्र

नई दिल्ली, 10 मार्च, 2016

का.व. 738(ब)—केन्द्रीय सरकार का यह समाधान हो गया है कि डाइक्लोफेनक + परेसिटामोल + मेनेसिक्यम ट्राइसिलिकेट की नियंत्रण खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपलब्ध हैं;

और इस विषय की केन्द्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केन्द्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विकित्सीय औषधि नहीं है;
Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition and whereas on the basis of the recommendations of the said Expert Committee, the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

Therefore, the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug Paracetamol + Domperidone + Caffeine which is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Paracetamol + Domperidone + Caffeine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 739(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Paracetamol + Domperidone + Caffeine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Paracetamol + Domperidone + Caffeine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

वर्ष 2016, 10 मार्च

कां.आ. 740(ब).—मंत्री सरकार का यह समावेश हो गया है कि एमोजियम फ्लोराइड + सोडियम साइडेट + क्लोरोफेरिनिग्राइन मेलेट + मैंचेल एमोजियम की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन की खतरा होने की संभावना है, जबकि उक्त औषधि के नुकसान अनुपात उपलब्ध हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार की यह सिफारिश की है कि उक्त औषधि के बारे में यह पारा गया है कि इसका कोई विकिरणीय अस्वस्थ नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समावेश हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रय/विनियमण, विक्रय और वितरण को प्रतिष्ठित करने विनियमित करना लोपकर्ति में आवश्यक और संबंधित है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन संबंधी अधिनियम, 1940 (1940 का 23) की धारा 26वा द्वारा प्रदत्त शर्तों का प्रयोग करते हुए, एमोजियम फ्लोराइड + सोडियम साइडेट + क्लोरोफेरिनिग्राइन मेलेट + मैंचेल की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रय/विनियमण, विक्रय और वितरण तकनीक प्रभाव से प्रतिष्ठित करती है।

[फ. नं. एक्स-11035/53/2014-डीएफसी]

कुंदल लाल शर्मा, संयुक्त सचिव
NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 740(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Ammonium Chloride + Sodium Citrate + Chlorpheniramine Maleate + Menthol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Ammonium Chloride + Sodium Citrate + Chlorpheniramine Maleate + Menthol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 741(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Paracetamol + Prochlorperazine Maleate is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Paracetamol + Prochlorperazine Maleate with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Paracetamol + Prochlorperazine Maleate** with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 742(E).— Whereas, the Central Government is satisfied that the use of the drug **Combikit of 3 tablets of Serratiopeptidase (enteric coated 20000 units) + Diclofenac Potassium & 2 tablets of Doxycycline** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **Combikit of 3 tablets of Serratiopeptidase (enteric coated 20000 units) + Diclofenac Potassium & 2 tablets of Doxycycline** with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 743(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Nimesulide + Paracetamol Suspension is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Nimesulide + Paracetamol Suspension with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
And Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Aceclofenac + Paracetamol + Famotidine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Aceclofenac + Paracetamol + Famotidine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 744(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Aceclofenac + Paracetamol + Famotidine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Aceclofenac + Paracetamol + Famotidine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 745(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Aceclofenac + Zinc Carnosine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

Now, therefore, on the basis of the recommendation of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of the said drug in the country;

With immediate effect.

New Delhi, the 10th March, 2016

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 746(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Paracetamol + Disodium Hydrogen Citrate + Caffeine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

With immediate effect.

New Delhi, the 10th March, 2016

K. L. SHARMA, Jt. Secy.
Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Paracetamol + Disodium Hydrogen Citrate + Caffeine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 747(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Paracetamol + DL Methionine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Paracetamol + DL Methionine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 748(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Disodium Hydrogen Citrate + Paracetamol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Disodium Hydrogen Citrate + Paracetamol with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 749(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Paracetamol + Caffeine + Codeine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Paracetamol + Caffeine + Codeine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 750(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Aceclofenac (SR) + Paracetamol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Aceclofenac (SR) + Paracetamol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 751(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Diclofenac + Paracetamol injection is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;
Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Diclofenac + Paracetamol injection** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

**NOTIFICATION**

New Delhi, the 10th March, 2016

S.O. 752(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Azithromycin + Cefixime** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Azithromycin + Cefixime** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 753(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Amoxicillin + Dicloxacillin is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Amoxicillin + Dicloxacillin with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 754(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Amoxicillin 250 mg + Potassium Clavulanate Diluted 62.5 mg is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expeditious in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Amoxicillin 250 mg + Potassium Clavulanate Diluted 62.5 mg with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 755(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Azithromycin + Levofloxacin is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Azithromycin + Levofloxacin with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
विभिन्न नई दिल्ली, 10 मार्च, 2016

कांग्रेस 756(ब)—केंद्रीय सरकार का यह समाधान हो गया है कि सेफिंसिम + लिनेजोलिड की नियत खुराक संयोजन औषधि के प्रयोग में मानव जीवन की खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुसंधान उपलब्ध हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय आँशिक नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिश के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण की प्रतिपीत करने वाले विनियमित करना लोकत्रित में आवश्यक और समीचित है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिश के आधार पर और औषधि और प्रमाण कानूनों अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, सेफिंसिम + लिनेजोलिड की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तकनीक प्रशासन से प्रतिष्ठा लेने का निर्देश दिया जा सकता है।

[फ. सं. एक्स-11035/53/2014-दीएफएसजी]
कुंदन लाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 756(E)—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Cefixime + Linezolid is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Cefixime + Linezolid with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

विभिन्न नई दिल्ली, 10 मार्च, 2016

कांग्रेस 757(ब)—केंद्रीय सरकार का यह समाधान हो गया है कि एमोसिलिं + सेफिंसिम + पोटाशियम व्यवस्थित ऐसी की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुसंधान उपलब्ध हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय आँशिक नहीं है;
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 757(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Amoxicillin + Cefixime + Potassium Clavulanic Acid** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Amoxicillin + Cefixime + Potassium Clavulanic Acid** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अधिवेशन

नई दिल्ली, 10 मार्च, 2016

का.आ. 758(अ).—केंद्रीय सरकार का यह समाधान हो गया है कि **ऑमिक्स्लाइन + नाइट्रोजोसाइड्स** की नियंत्रण बौद्धिक संयोजन औषधि के वस्तु के मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपलब्ध हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विश्लेषण समिति द्वारा जांच की गई है और उक्त विश्लेषण समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई गतिक्षणीय असंक्षिप्त नहीं है;

और उक्त विश्लेषण समिति की सिफारिश के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयांश विविधता, विक्रय और वितरण को तत्काल प्रभाव करने वाले तत्काल प्रभाव करती है।

[फा. सं. एम्स-11035/53/2014-डीएफक्सी]

कुंदन लाल शर्मा, संयुक्त सचिव
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 758(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Ofloxacin + Nitazoxanide** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Ofloxacin + Nitazoxanide** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 759(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Cefpodoxime Proxetil + Levofloxacin** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;
Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Cefpodoxime Proxetil + Levofloxacin** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

### NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 760(E).—Whereas, the Central Government is satisfied that the use of the drug **CombiKit of Azithromycin, Secnidazole and Fluconazole** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **CombiKit of Azithromycin, Secnidazole and Fluconazole** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 761(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Levofloxacin + Ornidazole + Alpha Tocopherol Acetate is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Levofloxacin + Ornidazole + Alpha Tocopherol Acetate with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 762(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Nimorazole + Ofloxacin is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Nimorazole + Ofloxacin with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 763(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Azithromycin + Ofloxacin** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Azithromycin + Ofloxacin** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 764(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Amoxycillin + Tinidazole** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;
And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Amoxycillin + Tinidazole with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 765(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Doxycycline + Serratiopeptidase is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Doxycycline + Serratiopeptidase with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 766(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Cefixime + Levofloxacin is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Cefixime + Levofloxacin with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
And Whereas the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is

of manufacture for sale, sale and distribution for human use of the said drug in the country;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central

Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition

powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government

is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Ofloxacin + Metronidazole + Zinc Acetate is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Ofloxacin + Metronidazole + Zinc Acetate with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 768(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Diphenoxylate + Atropine + Furazolidone** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Diphenoxylate + Atropine + Furazolidone** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 769(E).—Whereas, the Central Government is satisfied that the use of the drug **Combikit of Fluconazole Tablet, Azithromycin Tablet and Ornidazole Tablets** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;
Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **Combikit of Fluconazole Tablet, Azithromycin Tablet and Ornidazole Tablets** with immediate effect.

[F. No. X-11035/53/2014-DFQC]  
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 771(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Amoxycillin + Dicloxacillin + Serratiopeptidase is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Amoxycillin + Dicloxacillin + Serratiopeptidase with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केन्द्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण को प्रतिपिप्द करके विनिमयित करना लोकप्रिय में आवश्यक और समीचीन है;

अतः, अब, केन्द्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन समीक्षक संस्थान, 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त आदेशों का प्रयोग करते हुए, एजिप्रोमाइसिन + लेफ़पोडोक्सिम निलेक्ट्रोलील + मेथासोन मेथासोन मेथासोन मेथासोन के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तकाल प्रभाव से प्रतिपिप्द करती है।

[फा. सं. एम्स-11035/53/2014-डीएफ़एसई]

कुंदल लाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 772(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Azithromycin + Cefpodoxime is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Azithromycin + Cefpodoxime with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अधिसूचना

नई दिल्ली, 10 मार्च, 2016

फा.आ. 773(य)—केन्द्रीय सरकार का यह समाधान हो गया है कि लिमोफ्कैन + क्लोट्रिपोलिस + लेफ़पोडोक्सिम + मेथासोन मेथासोन की नियमित खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने वाली संभावना है, जबकि उक्त औषधि के गुणवत्ता अनुकूल उपलब्ध हैं;

और इस विवरण के केन्द्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केन्द्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विकसित औषधि नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केन्द्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण को प्रतिपिप्द करके विनिमयित करना लोकप्रिय में आवश्यक और समीचीन है;

अत:; अब, केन्द्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन समीक्षक संस्थान, 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त आदेशों का प्रयोग करते हुए, लिमोफ्कैन + क्लोट्रिपोलिस + लेफ़पोडोक्सिम + मेथासोन मेथासोन मेथासोन मेथासोन के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तकाल प्रभाव से प्रतिपिप्द करती है।

[फा. सं. एम्स-11035/53/2014-डीएफ़एसई]

कुंदल लाल शर्मा, संयुक्त सचिव
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 773(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Lignocaine + Clotrimazole + Ofloxacin + Beclomethasone is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Lignocaine + Clotrimazole + Ofloxacin + Beclomethasone with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 774(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Cefuroxime + Linezolid is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

K. L. SHARMA, Jt. Secy.
And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Cefuroxime + Linezolid** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

जद्धिष्ठन्ता

नई दिल्ली, 10 मार्च, 2016

क.आ. 775(अ)—केंद्रीय सरकार का यह समाधान हो गया है कि औफ्लोक्साइन + अरिन्डाजोल + जिंक बिसग्लिनिटेट की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के गुरून्त्र अनुकूल उपलब्ध हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय आश्चर्य नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए वितरण विनिमय, विक्रय और वितरण को प्रतिपित्त करके विनियमित करना लोकहित में आवश्यक और समीचीन है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रमाणण मामलों अधिनियम, 1940 (1940 का 23) की धारा 26 का 26 का प्रदत्त शक्तियों का प्रयोग करते हुए, औफ्लोक्साइन + अरिन्डाजोल + जिंक बिसग्लिनिटेट की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए वितरण विनिमय, विक्रय और वितरण तक प्रभाव में प्रतिपित्त करती है।

[फ. सं. एक्स-11035/53/2014-दीएएफ्सी]

कुंदन लाल शर्मा, मंत्री सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 775(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Ofloxacin + Ornidazole + Zinc Bisglycinate** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Ofloxacin + Ornidazole + Zinc Bisglycinate** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
अधिसूचना

नई दिल्ली, 10 मार्च, 2016

का.ः 778(अ)—केंद्रीय सरकार का यह समाधान हो गया है कि मेट्रोनिदाजोल + नारफ्लोक्सासिन की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के गुणित अनुकूल उपलब्ध है;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई प्राकृतिक औषधि नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानन्तर उपयोग के लिए विज्ञापन विनिमयां, विक्रय और वितरण की प्रतिपिद्ध करके विनियमित करना लोकप्रिय में आवश्यक और समीचीन है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रमाणन समग्र अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, मेट्रोनिदाजोल + नारफ्लोक्सासिन की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विज्ञापन विनिमयां, विक्रय और वितरण तत्काल प्रभाव से प्रतिपिद्ध करती है।

[फा.ः सं. 11035/53/2014-कृषकशृष्टि]

कुंदन लाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 776(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Metronidazole + Norfloxacin is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Metronidazole + Norfloxacin with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अधिसूचना

नई दिल्ली, 10 मार्च, 2016

का.ः 777(ब)—केंद्रीय सरकार का यह समाधान हो गया है कि एमोफ्लिसिलिन + फ्रोम्फेसाइन की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के गुणित अनुकूल उपलब्ध है;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विकृतिस्वरूप औषधि नहीं है;
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 777(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Amoxicillin + Bromhexine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Amoxicillin + Bromhexine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अधिसूचना

नई दिल्ली, 10 मार्च, 2016

काश्मी. 778(अ).—केंद्रीय सरकार का यह समाधान हो गया है कि सिपियोलोक्सासिस + प्लाटिकासिन + क्लोट्रिएक्सिल + नियोगाइडिसन की नियत बुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुविधा अनुकूल उपलब्ध है;

और इस विषय के केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जोन की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय चिकित्सा नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण को त्रुटिपूर्ण करके विनिमयित करना लोकतंत्र में आवश्यक और समीचीन है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रमाण नियम अधिनियम, 1940 (1940 का 23) की धारा 26 का द्वारा प्रदत्त अधिकार का प्रयोग करते हुए, सिपियोलोक्सासिस + प्लाटिकासिन + क्लोट्रिएक्सिल + नियोगाइडिसन की नियत बुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तकनीक प्रभाव से प्रतिपादित करती है।

[F. No. 11035/53/2014-3ीएफक्सी]

कृपया नव शर्मा, संयुक्त सचिव
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 778(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Ciprofloxacin + Fluticasone + Clotrimazole + Neomycin is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Ciprofloxacin + Fluticasone + Clotrimazole + Neomycin with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अधिकृतमा

नई दिल्ली, 10 मार्च, 2016

का.श. 779(अ)—केंद्रीय सरकार का यह समाधान हो गया है कि मेट्रोनिडाजोल + ट्रेत्राइक्लाइन की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन की खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकलन उपलब्ध हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बरे में यह पाया गया है कि इसका कोई सिफारिशी अधिकार नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विभिन्न विनिमय, विक्रय और वितरण को प्रतिपाद करने विनिमयित करना लोकहित में आवश्यक और समृद्ध है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन सामग्री अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रत्ये शक्तियों का प्रयोग करते हुए, मेट्रोनिडाजोल + ट्रेत्राइक्लाइन की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए, विभिन्न विनिमय, विक्रय और वितरण तक्ताल प्रभाव से प्रतिपाद करती है।

[फा. नं. एस्स-11035/53/2014-डी एफ एफ एसी]

कुंदन काल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 779(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Metronidazole + Tetracycline is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;
Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Metronidazole + Tetracycline with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 780(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Cephalexin + Neomycin + Prednisolone is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Cephalexin + Neomycin + Prednisolone with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
विवेकानन्द
नई दिल्ली, 10 मार्च, 2016

का.ख. 781(ब)—केंद्रीय सरकार का यह समाधान हो गया है कि एजिथ्रोमाइसिन + एम्ब्रोक्सोल की नियत बुराक संयोजन औषधि के प्रयोग से मानव जीवन की खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपलब्ध है;

और इस विषय के केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय असर नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण को प्रतिपिप्द करके विनियमित करना लोकहित में आवश्यक और समीचीन है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रमाणण समिति अधिनियम, 1940 (1940 का 23) की धारा 26(क) द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, एजिथ्रोमाइसिन + एम्ब्रोक्सोल की नियत बुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तकनीक प्रवाह में प्रतिपिप्द करती है।

[फा. सं. एक्स-11035/53/2014-कीएफकृष्णी]
कुंदल लाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 781(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Azithromycin + Ambroxol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Azithromycin + Ambroxol with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

विवेकानन्द
नई दिल्ली, 10 मार्च, 2016

का.ख. 782(ब)—केंद्रीय सरकार का यह समाधान हो गया है कि सिलिनिबाइन + बेटेप्रोसोल सार्फ्रेट + बेटेप्रोसोल टार्पेट्ट की नियत बुराक संयोजन औषधि के प्रयोग से मानव जीवन की खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपलब्ध हैं;

और इस विषय के केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय असर नहीं है;
and the Central Government is satisfied that the use of the drug fixed dose combination of Cilnidipine + Metoprolol Succinate + Metoprolol Tartrate is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Cilnidipine + Metoprolol Succinate + Metoprolol Tartrate with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 783(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of L-Arginine + Sildenafil is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of L-Arginine + Sildenafil with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 784(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Atorvastatin + Vitamin D3 + Folic Acid + Vitamin B12 + Pyridoxine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;
And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Atorvastatin + Vitamin D3 + Folic Acid + Vitamin B12 + Pyridoxine** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

**NOTIFICATION**

New Delhi, the 10th March, 2016

S.O. 785(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Metformin + Atorvastatin** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Metformin + Atorvastatin** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 786(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Clindamycin + Telmisartan is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Clindamycin + Telmisartan with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Olmesartan + Hydrochlorothiazide + Chlorthalidone** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Olmesartan + Hydrochlorothiazide + Chlorthalidone** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 787(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Olmesartan + Hydrochlorothiazide + Chlorthalidone** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Olmesartan + Hydrochlorothiazide + Chlorthalidone** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अधिसूचना

नई दिल्ली, 10 मार्च, 2016

का.आ. 788(अ).—केंद्रीय सरकार का यह समाधान हो गया है कि **एल-5-आइथोटेस्टरा/आइथोपोलेट फैक्ट्रीयम + एस्टेटोप्राम** की नियत बुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपलब्ध है;

और इस विषय के केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जौन की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका बोई विज्ञानी औषधि नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण को प्रतिपिप्त करने विनिमय करना लोकत्तम में आवश्यक और समीचीन है;

अतः अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्राप्त कर्तव्य गारंटी अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त अधिकारों का प्रयोग करते हुए, एल-5-आइथोटेस्टरा/आइथोपोलेट फैक्ट्रीयम + एस्टेटोप्राम की नियत बुराक संयोजन औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तकाल भाव से प्रतिपिप्त करती है।
NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 788(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of L-5-Methyltetrahydrofolate Calcium + Escitalopram is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of L-5-Methyltetrahydrofolate Calcium + Escitalopram with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Pholcodine + Promethazine** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 790(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Paracetamol + Promethazine** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Paracetamol + Promethazine** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
अधिसूचना
नई दिल्ली, 10 मार्च, 2016

का.अ. 791(ब)—केंद्रीय सरकार का यह समाधान हो गया है कि बीताहिस्टाइन + गिंक्गो बिलोबा एस्ट्रैक्ट +
विनपोसिटाइड + पिरासेटेम की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है,
जबकि उक्त औषधि के सुरक्षित अनुकूल उपयोग हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने
केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय अधिकार
नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त
औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमयां, विक्रय और वितरण को प्रतिपिप्त करके विनियमित करना लोकहित में आवश्यक और संवृत्ति है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रमाणन सामग्री
अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, बीताहिस्टाइन + गिंक्गो
बिलोबा एस्ट्रैक्ट + विनपोसिटाइड + पिरासेटेम की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ
विनिमयां, विक्रय और वितरण तकनीक प्रशासन से प्रतिपिप्त करती है।

[फ. सं. एक्स-11035/53/2014-वीएफसी]
कुंदन लाल शर्मा, संयुक्त सचिव

NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 791(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose
combination of Betahistine + Ginkgo Biloba Extract + Vinpocetine + Piracetam is likely to involve risk
to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central
Government and the said Expert Committee recommended to the Central Government that the said drug is
found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central
Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition
of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of
powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government
hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination
of Betahistine + Ginkgo Biloba Extract + Vinpocetine + Piracetam with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

अधिसूचना
नई दिल्ली, 10 मार्च, 2016

का.अ. 792(ब)—केंद्रीय सरकार का यह समाधान हो गया है कि सिट्रिनिक + ब्राइडाइल कार्बोमीड की नियत
खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल
उपयोग हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने
केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय अधिकार
नहीं है;
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 792(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Cetirizine + Diethyl Carbamazine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Cetirizine + Diethyl Carbamazine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 793(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Doxylamine + Pyridoxine + Mefenamic Acid + Paracetamol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendation of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Doxylamine + Pyridoxine + Mefenamic Acid + Paracetamol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Drotaverine + Clidinium + Chlordiazepoxide** with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

### NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 795(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Imipramine + Diazepam** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Imipramine + Diazepam** with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
अधिसूचना
नई दिल्ली, 10 मार्च, 2016

कार्य 798(ब)—केंद्रीय सरकार ने यह समाधान किया है कि प्लाप्टेंटिक्सोल + एसिटिलोनामा का नियम खुराक संयोजन आयुर्विज्ञान में प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुविधास्वामी अनुकूल है।

और इस विषय के केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जुड़ा होता है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका बीयर विकिततावी आयुर्विज्ञान नहीं है।

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान किया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रय व वितरण को प्रतिपन्न करने के विनियमों में आवश्यक और समीचीन है।

अतः, अन्य वेतन सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रामाण्य समीक्षा के अधिनियम, 1940 (1940 का 23) की धारा 26 के प्रदर्शन वल्लक्त का प्रयोग करते हुए, प्लाप्टेंटिक्सोल + एसिटिलोनामा का नियम खुराक संयोजन आयुर्विज्ञान का मानव उपयोग के लिए विक्रय व वितरण को प्रतिपन्न करता है।

[फा. सं. एक्स-11035/53/2014-कीएफसूची]
लाल अमर, संयुक्त सचिव

NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 796(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Flupentixol + Escitalopram is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Flupentixol + Escitalopram with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Paracetamol + Prochlorperazine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 797(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Paracetamol + Prochlorperazine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Paracetamol + Prochlorperazine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

नई दिल्ली, 10 मार्च, 2016

फा. 797(ि)।—केंद्रीय सरकार का यह समाधान है कि गामापेटामल + मकोन्वामिन + पाइरोडोक्सील + पामिनिन की नियंत्रित खुराक संयोजन औषधि के प्रयोग में मानव जीवन का खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल्य उपलब्ध है;

और इस विषय के केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जोन की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका बोरल विजिटरी औषधि नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि वेयर में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण को रक्षित करके नियंत्रित करना लोकप्रिय में आवश्यक और संमिली है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और अधिनियम सममत्री अधिनियम, 1940 (1940 का 23) की धारा 26का द्वारा प्रदत्त नियंत्रित का प्रयोग करते हुए, गामापेटामल + मकोन्वामिन + पाइरोडोक्सील + पामिनिन की नियंत्रित खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तत्पर प्रभाव से प्रतिष्ठित करती है।

[फा. 797(ि)]
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 798(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Gabapentin + Mecobalamin + Pyridoxine + Thiamine** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Gabapentin + Mecobalamin + Pyridoxine + Thiamine** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Imipramine + Chlordiazepoxide + Trifluoperazine + Trihexyphenidyl with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 800(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Chlorpromazine + Trihexyphenidyl is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Chlorpromazine + Trihexyphenidyl with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 801(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Ursodeoxycholic Acid + Silymarin is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Ursodeoxycholic Acid + Silymarin with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 802(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Metformin 1000/1000/500/500mg + Pioglitazone 7.5/7.5/7.5/7.5mg + Glimepiride 1/2/1/2mg is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendation of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Metformin 1000/1000/500/500mg + Pioglitazone 7.5/7.5/7.5/7.5mg + Glimepiride 1/2/1/2mg with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अभियुक्त

नई दिल्ली, 10 मार्च, 2016

का.आ. 803(अ).—केंद्रीय सरकार का यह समाधान हो गया है कि गिलिकाजाइड 80 रिग्रा. + मेटफार्मिन 325 रिग्रा. की नियाम खुराक संयोजन औषधि के प्रयोग से मानव जीवन की खत्तरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपलब्ध हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्ति विशेषज्ञ समिति द्वारा जोड़ी की गई है और उत्क विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई लिक्सिनीय औषधि नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण की प्रतिपाद करके विनियमित करना लोकतन्त्र में आवश्यक और समाजिक हैं;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन मामले अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त शक्तियों के प्रयोग करते हुए, गिलिकाजाइड 80 रिग्रा. + मेटफार्मिन 325 रिग्रा. की नियाम खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तत्काल प्रभाव से प्रतिपादित करती है।

[फा. ए. एक्स-11035/53/2014-कीएफकूडी]

कुंदल लाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 803(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Gliclazide 80 mg + Metformin 325 mg is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;
Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Gliclazide 80 mg + Metformin 325 mg** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 804(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Voglibose+ Metformin + Chromium Picolinate** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Voglibose+ Metformin + Chromium Picolinate** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 805(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Pioglitazone 7.5/7.5mg + Metformin 500/1000mg is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Pioglitazone 7.5/7.5mg + Metformin 500/1000mg with immediate effect.

[F. No. X-11035/53/2014-DFQC.]

K. L. SHARMA, Jt. Secy.
वर्तमान में देश के केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय असर नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मान्यता उपयोग के लिए विक्रयार्थ विनिमयार्थ, विक्रय और वितरण को प्रतिष्ठित करने विनियमित करना लोकतंत्र में अवश्यक और समीचीन है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधिविद और औषधि नियमांकन समिति अधिनियम, 1940 (1940 का 23) की धारा 26 के अंतर्गत अवधारणा का प्रयोग करते हुए, विधिविधान 1 मि.ग्रा./2 मि.ग्रा./3 मि.ग्रा. + पायोटिदलाइजन 15 मि.ग्रा./15 मि.ग्रा./15 मि.ग्रा. + मेटफाइमिन 1000 मि.ग्रा./1000 मि.ग्रा./ 1000 मि.ग्रा. की नियत खुराक संयोजन औषधि का मान्यता उपयोग के लिए विक्रयार्थ विनिमयार्थ, विक्रय और वितरण तत्काल प्रभाव ने प्रतिष्ठित करती है।

[फा. सं. एक्स-11035/53/2014-दीएफ्रीसी]
कुंदन नाथ शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 806(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Glimepiride 1mg/2mg/3mg + Pioglitazone 15mg/15mg/15mg + Metformin 1000mg/1000mg/1000mg is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendation of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Glimepiride 1mg/2mg/3mg + Pioglitazone 15mg/15mg/15mg + Metformin 1000mg/1000mg/1000mg with immediate effect.

[F. No. X-11035/53/2014-DFQC.]
K. L. SHARMA, Jt. Secy.

बिहार सरकार

नई दिल्ली, 10 मार्च, 2016

क.श्र.807(३)—केन्द्रीय सरकार का यह समाधान हो गया है कि विधिविधान 1 मि.ग्रा./2 मि.ग्रा. + पायोटिदलाइजन 15 मि.ग्रा./15 मि.ग्रा./15 मि.ग्रा. + मेटफाइमिन 850 मि.ग्रा./850 मि.ग्रा. की नियत खुराक संयोजन औषधि के प्रयोग से मान्य जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुलक्षित अनुकूल उपलब्ध हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय असर नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मान्यता उपयोग के लिए विक्रयार्थ विनिमयार्थ, विक्रय और वितरण को प्रतिष्ठित करके विनियमित करना लोकतंत्र में आवश्यक और समीचीन है;
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 807(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Glimepiride 1mg/2mg+ Pioglitazone 15mg/15mg + Metformin 850mg/850mg is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Glimepiride 1mg/2mg+ Pioglitazone 15mg/15mg + Metformin 850mg/850mg with immediate effect.

[F. No. X-11035/53/2014-DFQC.]

K. L. SHARMA, Jt. Secy.

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और आयुष्मान और प्रामाण्य सामग्री अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रत्याशित अंशों का प्रयोग करते हुए, मेटफार्मिन 850 मिम.ए./850 मिम.ए. + पायोसिटाजॉन 15 मिम.ए./15 मिम.ए. + ग्लिमिपिडाइड 2 मिम.ए. की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमयां, विक्रय और वितरण तकनीक प्रबंध से प्रतिबिंदू करती है।
NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 808(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Metformin 850mg + Pioglitazone 7.5 mg + Glimepiride 2mg is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas, the drug is likely to involve risk to human beings whereas safer alternatives to the said drug are available; the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Metformin 850mg + Pioglitazone 7.5 mg + Glimepiride 2mg with immediate effect.

[F. No. X-11035/53/2014-DFQC.]

K. L. SHARMA, Jt. Secy.

NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 809(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Metformin 850mg + Pioglitazone 7.5 mg + Glimepiride 1mg is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;
And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Metformin 850mg + Pioglitazone 7.5 mg + Glimepiride 1mg with immediate effect.

[F. No. X-11035/53/2014-DFQC.]
K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 810(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Metformin 500mg/500mg+Gliclazide SR 30mg/60mg + Pioglitazone 7.5mg/7.5mg is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Metformin 500mg/500mg+Gliclazide SR 30mg/60mg + Pioglitazone 7.5mg/7.5mg with immediate effect.

[F. No. X-11035/53/2014-DFQC.]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 811(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Voglibose + Pioglitazone + Metformin is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Voglibose + Pioglitazone + Metformin with immediate effect.

[F. No. X-11035/53/2014-DFQC.]

K. L. SHARMA, Jt. Secy.
Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Metformin + Bromocriptine with immediate effect.

[F. No. X-11035/53/2014-DFQC.]
K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 812(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Metformin + Bromocriptine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Metformin + Bromocriptine with immediate effect.

[F. No. X-11035/53/2014-DFQC.]
K. L. SHARMA, Jt. Secy.

नई दिल्ली, 10 मार्च, 2016

का.श्र. 813(अ).—सरकार का यह समाधान हो गया है कि मेथाइकोबलािमन + मेथाइकोबलािमन + मेथाइकोबलािमन की नियत बुराक संयोजन औषधि के प्रयोग से मानव जीवन की खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपलब्ध है;

और उस विषय की सरकार द्वारा नियमित विशेषज्ञ समिति द्वारा जाँच की गई है और उक्त विशेषज्ञ समिति ने सरकार की यह सीमित की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय आदेश नहीं है;

और उक्त विशेषज्ञ समिति की सीमित की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय आदेश नहीं है;

और उक्त विशेषज्ञ समिति की सीमित की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय आदेश नहीं है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सीमित की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय आदेश नहीं है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सीमित की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय आदेश नहीं है.

[फा. सं. एक्स-11035/53/2014-डीएफसीसी]
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 813(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Metformin + Glimepiride + Methylcobalamin is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Metformin + Glimepiride + Methylcobalamin with immediate effect.

[F. No. X-11035/53/2014-DFQC.]

K. L. SHARMA, Jt. Secy.

विधेयक

नई दिल्ली, 10 मार्च, 2016

का.शा. 814(ब).—केंद्रीय सरकार का यह समाधान हो गया है कि पायोलिटाजोन 30 मिग्र. + मेटफार्मिन 500 मिग्र. की नियत खुराक संयोजन औषधि के प्रयोग से मानव स्वास्थ्य को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपयोग है;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जाँच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विचित्रित औषधित्व नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमयांश, विक्रय और वितरण के तत्त्वांशित करने लोकहित में आवश्यक और समीचीन है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन समीक्षक अधिनियम, 1940 (1940 का 23) की धारा 26(२) द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, पायोलिटाजोन 30 मिग्र. + मेटफार्मिन 500 मिग्र. की नियत खुराक संयोजन औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमयांश, विक्रय और वितरण तत्त्वांशित प्रभाव से प्रतिरोध करती है।

[फा. सं. एक्स-11035/53/2014-डीईएफएसी]

कुंदन लाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 814(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Pioglitazone 30 mg + Metformin 500 mg is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;
And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Pioglitazone 30 mg + Metformin 500 mg with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 815(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Glimepiride + Pioglitazone + Metformin is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Glimepiride + Pioglitazone + Metformin with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Glipizide 2.5mg + Metformin 400 mg is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Notwithstanding anything contained in any other law for the time being in force, the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Glipizide 2.5mg + Metformin 400 mg with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 817(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Pioglitazone 15mg + Metformin 850 mg is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Pioglitazone 15mg + Metformin 850 mg with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 818(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Metformin ER + Gliclazide MR + Voglibose is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Metformin ER + Gliclazide MR + Voglibose with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

बंधनसूचना

नई दिल्ली, 10 मार्च, 2016

काा.आ. 819(ब)।— केंद्रीय सरकार का यह समाधान हो गया है कि कोमिषन पोलिनिकाटिनेट + मेटफार्मिन की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सूचित अनुकूल उपलब्ध हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय ओषधि नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनियमाण, विक्रय और वितरण को प्रतिपाद्य करके विनियमित करना लोकतंत्र में आवश्यक और समीचीन हैं;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रशासन समस्या अधिनियम, 1940 (1940 का 23) की धारा 26क हारा प्रतिलिपि का प्रयोग करते हुए, कोमिषन पोलिनिकाटिनेट + मेटफार्मिन की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनियमाण, विक्रय और वितरण तक्तल प्रभाव में प्रतिस्थापित करती है।

[फा. सं. एक्स-11035/53/2014-दीएफाक्ष्युमी]
कुंदल लाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 819(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Chromium Polynicotinate + Metformin is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;
And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Chromium Polynicotinate + Metformin** with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

**NOTIFICATION**

New Delhi, the 10th March, 2016

S.O. 820(E).— Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Metformin + Gliclazide + Pioglitazone + Chromium Polynicotinate** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Metformin + Gliclazide + Pioglitazone + Chromium Polynicotinate** with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 821(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Metformin + Gliclazide + Chromium Polynicotinate is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Metformin + Gliclazide + Chromium Polynicotinate with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 822(E).— Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Glibenclamide + Metformin (SR)+ Pioglitazone** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Glibenclamide + Metformin (SR)+ Pioglitazone** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अधिसूचना

नई दिल्ली, 10 मार्च, 2016

का.आ. 823(ब)—केंद्रीय सरकार का यह समाधान हो गया है कि **मेटफार्मिन (एस एर) 500 मिग्रा. + पायोलिटाजोन 15 मि.ग्रा. + स्लिमप्राइड 3 मि.ग्रा.** की नियत युग्म संयोजन आयुष्य के यथार्थ सत्ता की खतरा होने की संभावना है, जबकि उक्त आयुष्य के सुरक्षित अनुकूल उपलब्ध हैं;

और इस संबंध की केंद्रीय सरकार के नियुक्त विषयक समिति के ज्ञान की गई है और उक्त विषयक समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त आयुष्य के बारे में यह पाया गया है कि इसका कोई चिकित्सीय आयुष्य नहीं है;

और उक्त विषयक समिति की सिफारिश के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त आयुष्य के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण को प्रतिपिप्त करके विनियमित करना लोकहर भी आवश्यक और समीचीन है;

अतः, अब, केंद्रीय सरकार, उक्त विषयक समिति की सिफारिशों के आधार पर और आयुष्य और प्रमाणण नामात्मक अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रवक्त शक्तियों का प्रयोग करते हुए, **मेटफार्मिन (एस एर) 500 मिग्रा. + पायोलिटाजोन 15 मि.ग्रा. + स्लिमप्राइड 3 मि.ग्रा.** की नियत युग्म संयोजन आयुष्य का मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तकाल्प प्रभाव से प्रतिपिप्त करती है।

[फा. सं. एक्स-11035/53/2014-ईकेकसूची]
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 823(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Metformin (Sustained Release) 500mg + Pioglitazone 15 mg + Glimepiride 3mg is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Metformin (Sustained Release) 500mg + Pioglitazone 15 mg + Glimepiride 3mg with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 824(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Metformin (Sustainded Release) 500mg + Pioglitazone 15 mg + Glimepiride 3mg is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;
And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Metformin (SR) 500mg + Pioglitazone 5mg** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 825(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Chloramphenicol + Beclomethasone + Clomitrizamole + Lignocaine** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Chloramphenicol + Beclomethasone + Clomitrizamole + Lignocaine** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 826(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Clotrimazole + Ofloxacin + Lignocaine + Glycerine and Propylene Glycol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Clotrimazole + Ofloxacin + Lignocaine + Glycerine and Propylene Glycol with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
अधिसूचना

नई दिल्ली, 10 मार्च, 2016

का. आ. 827(ज)—केंद्रीय सरकार का यह समाधान हो गया है कि क्लोराम्फेनिकोल + लिग्नोकेन + बीटामेथासोन + क्लोट्रिमजोल + ओफ्लोक्सासिन + एंटीपिरीन की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल प्रयोग हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय आधार नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विकृत्यार्थ विनिमय, विक्रय और वितरण की प्रतिपिध करके विनियमित करना लोकत्रित में आवश्यक और समाजीत है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रमाणन सामग्री अधिनियम, 1940 (1940 का 23) की धारा 26 के द्वारा प्रदत्त क्षमताओं का प्रयोग करते हुए, क्लोराम्फेनिकोल + लिग्नोकेन + बीटामेथासोन + क्लोट्रिमजोल + ओफ्लोक्सासिन + एंटीपिरीन की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विकृत्यार्थ विनिमय, विक्रय और वितरण तकनीक प्रबन्ध के प्रतिपिध करते हैं।

[फा. स. ए.स्स-11035/53/2014-धीरेंद्रकृष्ण]
केंद्र लाल शर्मा, मंत्री (सचिव)

NOTIFICATION

New Delhi, the 10th March, 2016

S.O.827(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Chloramphenicol + Lignocaine + Betamethasone + Clotrimazole + Ofloxacin + Antipyrine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Chloramphenicol + Lignocaine + Betamethasone + Clotrimazole + Ofloxacin + Antipyrine with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.828(E).—Whereas, the Central Government is satisfied that the use of the drug *fixed dose combination of Ofloxacin + Clotrimazole + Betamethasone + Lignocaine* is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug *fixed dose combination of Ofloxacin + Clotrimazole + Betamethasone + Lignocaine* with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.829(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Gentamicin Sulphate + Clotrimazole + Betamethasone + Lignocaine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Gentamicin Sulphate + Clotrimazole + Betamethasone + Lignocaine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.830(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Clotrimazole + Beclomethasone + Ofloxacin + Lignocaine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Clotrimazole + Beclomethasone + Ofloxacin + Lignocaine with immediate effect.

[F. No. X-11035/53/2014-DHQ]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.831(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Becloethasone + Clotrimazole + Chloramphenicol + Gentamycin + Lignocaine Ear drops is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Becloethasone + Clotrimazole + Chloramphenicol + Gentamycin + Lignocaine Ear drops with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.832(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Flunarizine + Paracetamole + Domperidone is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Flunarizine + Paracetamole + Domperidone with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
संयोजन औषिध के लिए आधिकारिक आदेश, 1940 (1940 का 23)

106

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Rabeprazole + Zinc Carnosine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.834(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Magaldrate + Famotidine + Simethicone is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Magaldrate + Famotidine + Simethicone with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.835(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Cyproheptadine + Thiamine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Cyproheptadine + Thiamine with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
नई दिल्ली, 10 मार्च, 2016

का.आ. 836(ब)— केंद्रीय सरकार का यह समाधान हो गया है कि मगाल्ड्रेट + रेनिटिडिन + पेनक्टिन + होमपेट्रेडिन की लियत खुराक संयोजन औषधि के प्रयोग में मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकल्प उपलब्ध हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार की यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय औषधिय्य नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण को प्रतिबंध करके विनियमित करना लोकहित में आवश्यक और समीचीन है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रमाणन सामग्री अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, मगाल्ड्रेट + रेनिटिडिन + पेनक्टिन + होमपेट्रेडिन की लियत खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तकनीक प्रभाव से प्रतिबंध करती है।

[फ. ए. एस-11035/53/2014-डीएफजीसी]
कुंदन लाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O.836(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Magaldrate + Ranitidine + Pancreatin + Domperidone is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Magaldrate + Ranitidine + Pancreatin + Domperidone with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.837(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Ranitidine + Magaldrate + Simethicone is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Ranitidine + Magaldrate + Simethicone with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
बविःसूचना

नई दिल्ली, 10 मार्च, 2016

काला. 838(अ)—केंद्रीय सरकार का यह समाधान हो गया है कि मगाल्ड्रेट + पापेन + फंगल डाइस्टेस + सिमिथकोन की नियत खुराक संयोजन आधिकृत द्वारा यथार्थ रूप से मानव जीवन की खतरा होने की संभावना है, जबकि उक्त आधिकृत के सुरक्षित अनुकल्प उपलब्ध है;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार की यह सिफारिश की है कि उक्त आधिकृत के बारे में यह पाया गया है कि इसका कोई चिकित्सीय आवश्यकता नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त आधिकृत के मानव उपयोग के लिए विक्रयार्थ विनिमयार्थ, विक्रय और वितरण की प्रतिपद्ध करके विनियमित करना लोकहित में आवश्यक और समीचीन है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और आधिकृत और प्रमाणण स्मारकी अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त अधिनियम का यथार्थ रूप से प्रयोग करते हुए, मगाल्ड्रेट + पापेन + फंगल डाइस्टेस + सिमिथकोन की नियत खुराक संयोजन आधिकृत का मानव उपयोग के लिए विक्रयार्थ विनिमयार्थ, विक्रय और वितरण तत्काल अनुमति से प्रतिपद्ध करती है।

[फा. सं. एस्स-11035/53/2014-कीएफकेसी]
कुंदन लाल भर्म, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O.838(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Magaldrate + Papain + Fungal Diastase + Simethicone is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Magaldrate + Papain + Fungal Diastase + Simethicone with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.839(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Rabeprazole + Zinc + Domperidone is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Rabeprazole + Zinc + Domperidone with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.840(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Famotidine + Oxytacaine + Magaldrate is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Famotidine + Oxytacaine + Magaldrate with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.841(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Ranitidine + Domperidone + Simethicone is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Ranitidine + Domperidone + Simethicone with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.842(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Alginic Acid + Sodium Bicarbonate + Dried Aluminium Hydroxide + Magnesium Hydroxide is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Alginic Acid + Sodium Bicarbonate + Dried Aluminium Hydroxide + Magnesium Hydroxide with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.843(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Clidinium + Paracetamol + Dicyclomine + Activated Dimethicone is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Clidinium + Paracetamol + Dicyclomine + Activated Dimethicone with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.844(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Furazolidone + Metronidazole + Loperamide is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Furazolidone + Metronidazole + Loperamide with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.845(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Rabeprazole + Diclofenac + Paracetamol** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Rabeprazole + Diclofenac + Paracetamol** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
विधिसूचना
नई दिल्ली, 10 मार्च, 2016

का.आ. 846(आ)— केंद्रीय सरकार का यह समाधान हो गया है कि रेनिटिडीन + मागाल्ड्रेट की नियन्त्रित खुराक संयोजन औषधि के प्रयोग से मानव जीवन की खतरा होती है की, जबकि उक्त औषधि के सुरक्षित अनुकूल उपलब्ध है।

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा सांचें गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय औषधि नहीं है।

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण को प्रतिपित्त करके विनियमित करना लोकहित में आश्वयक और समीचीन है।

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रमाणन समीक्षक अधिनियम, 1940 (1940 का 23) की धारा 26 क द्वारा प्रदत्त शर्तों का प्रयोग करते हुए, रेनिटिडीन + मागाल्ड्रेट की नियन्त्रित खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तकाल प्रभाव से प्रतिपित्त करती है।

कुंदन वाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O.846(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Ranitidine + Magaldrate is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Ranitidine + Magaldrate with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.847(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Norfloxacin + Metronidazole + Zinc Acetate is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Norfloxacin + Metronidazole + Zinc Acetate with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
विधिसूचना

नई दिल्ली, 10 मार्च, 2016

का.आ. 848(म)।— केंद्रीय सरकार का यह समाधान हो गया है कि जिंक कार्नोसाइन + ओक्सेटाकाइन की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपलब्ध हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जौंच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय औषधित्व नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रेता और वितरक को प्रतिपिठ करके विनियमित करना लोकहित में आवश्यक और समीचीन है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन समिति अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, जिंक कार्नोसाइन + ओक्सेटाकाइन की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रेता और वितरक तक्ताल प्रभाव से प्रतिपिठ करती है।

[फा. सं. एक्स-11035/53/2014-डीएफसीक्सी]
कुंदन लाल भार्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O.848(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Zinc Carnosine + Oxetacaine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Zinc Carnosine + Oxetacaine with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
नई दिल्ली, 10 मार्च, 2016

कां.आ. 849(E) — केंद्रीय सरकार का यह समाधान हो गया है कि ओक्सेटाकैन + मगाल्ड्रेट + फेमोटिडीन का नियत खुराक संयोजन औषधि के प्रयोग में मानव जीवन को खतारी होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपलब्ध हैं;

परंतु इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय औषधि नहीं है;

परंतु उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमयार्थ, विक्रय और वितरण की प्रतिपिद्ध करके विनियमित करना लोकहित में आवश्यक और समीचीन हैं;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन नामग्री अधिनियम, 1940 (1940 का 23) की धारा 26का द्वारा प्रस्तावित शक्तियों का प्रयोग करते हुए, ओक्सेटाकैन + मगाल्ड्रेट + फेमोटिडीन का नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमयार्थ, विक्रय और वितरण तक्ताल प्रभाव से प्रतिपिद्ध करती है।

[फ.सं. एक्स-11035/53/2014-हीएक्सक्स्क्सी]
कुंदल लाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O.849(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Oxetacaine + Magaldrate + Famotidine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Oxetacaine + Magaldrate + Famotidine with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
बिधिसूचना

नई दिल्ली, 10 मार्च, 2016

का.आ. 850(अ)— केंद्रीय सरकार का यह समाधान हो गया है कि पंटोप्राजोल (एंटरिक कॉटिड टेबलेट के रूप में) + विंड कार्नोसाइन (फिल्म कॉटिड टेबलेट के रूप में) की नियत खुराक संयोजन आयुर्धि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त आयुर्धि के सुरक्षित अनुकूल उपलब्ध है;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त आयुर्धि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय आश्चर्य नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त आयुर्धि के मानव उपयोग के लिए विक्रयार्थ वितरित, विक्रय और वितरण की प्रतिपादन करने विीयविधि करना लोकर्षित में आवश्यक और समीचीन है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और आयुर्धि और प्रमाणन नामक अधिनियम, 1940 (1940 का 23) की धारा 26(क) द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, पंटोप्राजोल (एंटरिक कॉटिड टेबलेट के रूप में) + विंड कार्नोसाइन (फिल्म कॉटिड टेबलेट के रूप में) की नियत खुराक संयोजन आयुर्धि का मानव उपयोग के लिए विक्रयार्थ वितरित, विक्रय और वितरण तत्काल प्रभाव से प्रतिपादन करती है।

[फ. स. एस-11035/53/2014-कीएफक्सूमी]
कुंदन लाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O.850(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Pantoprazole (as Enteric Coated Tablet) + Zinc Carnosine (as Film Coated Tablets) is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Pantoprazole (as Enteric Coated Tablet) + Zinc Carnosine (as Film Coated Tablets) with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.851(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Zinc Carnosine + Magnesium Hydroxide + Dried Aluminium Hydroxide + Simethicone is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Zinc Carnosine + Magnesium Hydroxide + Dried Aluminium Hydroxide + Simethicone with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
विधिसूचना
नई दिल्ली, 10 मार्च, 2016।

का.ए. 852(ब) — केंद्रीय सरकार का यह समाधान हो गया है कि जिक कार्नॉसाइन+ सुकालफेट मिश्रण का नियम खुराक संयोजन औषधि के प्रयोग से मानव जीवन की खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपयोग है;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय आवश्यकता नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमया, विक्रय और वितरण को प्रतिपिध रखने के विनियमित करना लोकतंत्र में आवश्यक और समीचित है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन समीक्षा अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, जिक कार्नॉसाइन+ सुकालफेट के नियम खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमया, विक्रय और वितरण तक्षत्र प्रभाव से प्रतिपिध करती है।

[फ. न. एसएस-11035/53/2014-डीएफसी]
कृपया नव श्रम, संयुक्त सचिव

NOTIFICATION
New Delhi, the 10th March, 2016

S.O.852(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Zinc Carnosine + Sucralfate is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Zinc Carnosine + Sucralfate with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.853(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Mebheverine & Inner HPMC capsule (Streptococcus Faecalis + Clostridium Butyricum + Bacillus mesentricus + Lactic Acid Bacillus) is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Mebheverine & Inner HPMC capsule (Streptococcus Faecalis + Clostridium Butyricum + Bacillus mesentricus + Lactic Acid Bacillus) with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.854(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Clindamycin + Clotrimazole + Lactic Acid Bacillus is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Clindamycin + Clotrimazole + Lactic Acid Bacillus with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.855(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Sildenafil + Estradiol Valerate is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Sildenafil + Estradiol Valerate with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.856(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Clomifene Citrate + Ubidecarenone + Zinc + Folic Acid + Methylcobalamin + Pyridoxine + Lycopene + Selenium + Levocarnitine Tartrate + L-Arginine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Clomifene Citrate + Ubidecarenone + Zinc + Folic Acid + Methylcobalamin + Pyridoxine + Lycopene + Selenium + Levocarnitine Tartrate + L-Arginine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.857(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Thyroxine + Pyridoxine + Folic Acid is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Thyroxine + Pyridoxine + Folic Acid with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.858(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Gentamycin + Dexamethasone + Chloramphenicol + Tobramycin + Ofloxacin is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Gentamycin + Dexamethasone + Chloramphenicol + Tobramycin + Ofloxacin with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.859(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Dextromethorphan + Levocetirizine + Phenylephrine + Zinc is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Dextromethorphan + Levocetirizine + Phenylephrine + Zinc with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
नई दिल्ली, 10 मार्च, 2016

[फा. सं. एक्स-11035/53/2014-डीएफक्सी]

NOTIFICATION

New Delhi, the 10th March, 2016

S.O.860(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Nimesulide + Loratadine + Phenylephrine + Ambroxol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Nimesulide + Loratadine + Phenylephrine + Ambroxol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
बाध्यसूचना

नई दिल्ली, 10 मार्च, 2016

काल. 861(अ)—केंद्रीय सरकार का यह समाधान हो गया है कि ब्रोमहेक्सीन + फेनाइलेफरीन + च्लोरफेनिलिमेन बेलेट की नियमित खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होता है। जबकि उक्त औषधि के लक्षण अनुकूल उपलब्ध हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय उपचार नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण की प्रतिपिध करके विनियमित करना लोकहित में आवश्यक और समीचीन हैं;

अतः, अनु, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रयोग संस्थानी अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त अंशों का प्रयोग करते हुए, ब्रोमहेक्सीन + फेनाइलेफरीन + च्लोरफेनिलिमेन बेलेट की नियमित खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण लोकहित से प्रतिपिध करती है।

[फास. एस. 11035/53/2014-डीएफसी]

कुंदल लाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O.861(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Bromhexine + Phenylephrine + Chlorephehramine Maleate is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Bromhexine + Phenylephrine + Chlorephehramine Maleate with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.862(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Dextromethorphan + Bromhexine + Guaiphenesin is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Dextromethorphan + Bromhexine + Guaiphenesin with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.863(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Paracetamol + Loratadine + Phenylephrine + Dextromethorphan + Caffeine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Paracetamol + Loratadine + Phenylephrine + Dextromethorphan + Caffeine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.864(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Nimesulide + Phenylephrine + Caffeine + Levocetirizine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Nimesulide + Phenylephrine + Caffeine + Levocetirizine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.865(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Azithromycin + Acebrophylline** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Azithromycin + Acebrophylline** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.866(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Diphenhydramine + Terpine + Ammonium Chloride + Sodium Chloride + Menthol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Diphenhydramine + Terpine + Ammonium Chloride + Sodium Chloride + Menthol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.867(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Nimesulide + Paracetamol + Cetirizine + Phenylephrine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Nimesulide + Paracetamol + Cetirizine + Phenylephrine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION  

New Delhi, the 10th March, 2016

S.O.868(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Paracetamol + Loratadine + Dextromethophan + Pseudoephedrine + Caffeine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Paracetamol + Loratadine + Dextromethophan + Pseudoephedrine + Caffeine with immediate effect.

[F. No. X-11035/53/2014-DFQC]  
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O.869(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Chlorpheniramine Maleate + Dextromethorphan + Dextromethorphan + Guaiphenesin + Ammonium Chloride + Menthol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Chlorpheniramine Maleate + Dextromethorphan + Dextromethorphan + Guaiphenesin + Ammonium Chloride + Menthol with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
New Delhi, the 10th March, 2016

S.O.870(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Chlorpheniramine Maleate + Ammonium Chloride + Sodium Citrate is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Chlorpheniramine Maleate + Ammonium Chloride + Sodium Citrate with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 871(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Cetirizine + Phenylephrine + Paracetamol + Zinc Gluconate** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

    And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

    AndWhereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

    Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Cetirizine + Phenylephrine + Paracetamol + Zinc Gluconate** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
नई दिल्ली, 10 मार्च, 2016

फा. आ. 872(ब)—केंद्रीय सरकार का यह समाधान हो गया है कि एम्ब्रोक्सोल + गुआइफेनेसिन +अमोनियम ब्लोराइड +फिनाइफरीन +ब्लोरेफराइमाइन मेलिएट +मेंथोल की नियम खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के पुरक्षित अनुकूल उपलब्ध हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाए गया है कि इसका कोई चिकित्सीय आपत्ति नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विज्ञापन विनिमां, विज्ञ और वितरण को प्रतिपाद करने विनियमित करना लोकसत्ता में आवश्यक और समीचीन है;

अत: अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन समग्री अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त अधिकारों का प्रयोग करते हुए, एम्ब्रोक्सोल + गुआइफेनेसिन +अमोनियम ब्लोराइड +फिनाइफरीन +ब्लोरेफराइमाइन मेलिएट +मेंथोल की नियम खुराक संयोजन औषधि का मानव उपयोग के लिए विज्ञापन विनिमां, विज्ञ और वितरण तत्काल प्रभाव से प्रतिपादित करती है।

[फा. आ. एक्स-11035/53/2014-डीएफजीसी]
K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 872(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Ambroxol + Guaiphenesin + Ammonium Chloride + Phenylephrine + Chlorpheniramine Maleate + Menthol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Ambroxol + Guaiphenesin + Ammonium Chloride + Phenylephrine + Chlorpheniramine Maleate + Menthol with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 873(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Dextromethorphan + Bromhexine + Chlorpheniramine Maleate + Guaiphenesin is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Dextromethorphan + Bromhexine + Chlorpheniramine Maleate + Guaiphenesin with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 874(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Levocetirizine + Ambroxol + Phenylephrine + Guaiphenesin is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Levocetirizine + Ambroxol + Phenylephrine + Guaiphenesin with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of such medicines as found to have no therapeutic justification; and whereas, the matter has been examined by an Expert Committee appointed by the Central Government, the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug Dextromethorphan + Chlorpheniramine + Chlorpheniramine Maleate with immediate effect.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 875(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Dextromethorphan + Chlorpheniramine + Chlorpheniramine Maleate is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Dextromethorphan + Chlorpheniramine + Chlorpheniramine Maleate with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 876(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Cetirizine + Ambroxol + Guaiphenesin + Ammonium Chloride + Phenylephrine + Menthol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Cetirizine + Ambroxol + Guaiphenesin + Ammonium Chloride + Phenylephrine + Menthol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
S.O. 877(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Chlorpheniramine + Phenylephrine + Caffeine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendation of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Chlorpheniramine + Phenylephrine + Caffeine with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 878(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Dextromethorphan + Triprolidine + Phenylephrine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendation of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government
hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Dextromethorphan + Triprolidine + Phenylephrine with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

अधिसूचना

नई दिल्ली, 10 मार्च, 2016

का.वा. 879(ब)—केन्द्रीय सरकार का यह समाधान हो गया है कि टेरपिनहाइड्रेट+ डेक्सट्रोमेथोर्फ़ + मेंथोल की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपलब्ध हैं;

और इस विषय के केन्द्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केन्द्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय औषधि नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केन्द्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विज्ञापन विनिमय नहीं है और वितरण की प्रतिष्ठा करने से आश्वासन और समीचीन है;

अतः अब, केन्द्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन सामग्री अधिनियम, 1940 (1940 का 23) की धारा 26(क) द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, टेरपिनहाइड्रेट + डेक्सट्रोमेथोर्फ़ + मेंथोल की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विज्ञापन, विज्ञापन और वितरण तत्काल प्रभाव से प्रतिष्ठित करती है।

[फ. सं. एक्स-11035/53/2014-टीएफक्सी]
कृतनारायण शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 879(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Terpinhyd,rate + Dextromethorphan + Menthol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Terpinhyd,rate + Dextromethorphan + Menthol with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 880(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Dextromethorphan + Phenylephrine + Zinc Gluconate + Menthol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Dextromethorphan + Phenylephrine + Zinc Gluconate + Menthol with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

S.O. 881(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Chlorpheniramine + Codeine + Sodium Citrate + Menthol Syrup is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Chlorpheniramine + Codeine + Sodium Citrate + Menthol Syrup with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 882(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Enrofloxacin + Bromhexin** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Enrofloxacin + Bromhexin** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 883(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Bromhexine + Dextromethorphan + Phenylephrine + Menthol** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Bromhexine + Dextromethorphan + Phenylephrine + Menthol** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अधिसूचना
नई दिल्ली, 10 मार्च, 2016

का.आ. 884(ब).—केंद्रीय सरकार का यह समाधान हो गया है कि लेवोफ्लोक्साइन + ब्रोम्हेक्सीन की नियत युगल संयोजन औषधि के प्रयोग से मानव जीवन की खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपचार हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विकिर्त औषधि नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि इस के मानव उपयोग के लिए बिरुखार्ड विनिमय, विक्रय और वितरण की प्रतिपिंड करके विनियमित करना लोकहित में आवश्यक और संचालक है;

अत:; जब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और उक्त औषधि और प्रसाधन सामग्री अधिनियम, 1940 (1940 का 23) की धारा 26 के द्वारा प्रदत्त शर्तों का प्रयोग करते हुए, लेवोफ्लोक्साइन + ब्रोम्हेक्सीन की नियत युगल संयोजन औषधि का मानव उपयोग के लिए बिरुखार्ड विनिमय, विक्रय और वितरण तक्कर प्रभाव से प्रतिपिंड करती है।

[फ. म. एक्स-11035/53/2014-डीएफ्सी]

कुंदन लाल शर्मा, संयुक्त सचिव

NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 884(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Levofloxacin + Bromhexine** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;
And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Levofloxacin + Bromhexine** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

---

**NOTIFICATION**

New Delhi, the 10th March, 2016

S.O. 885(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Levocetirizine + Ranitidine** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Levocetirizine + Ranitidine** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
सो. 886 (E)।—केन्द्रीय सरकार का यह समाधान हो गया है कि लैवोसिट्रिज फेरॉनिफरीन + एम्ब्रोकोल + ग्वाइफेनिसिंस + पारासिटामॉल की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपलब्ध हैं;

और इस विषय की केन्द्रीय सरकार द्वारा नियुक्ति विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केन्द्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई सिफारिशी औषधि नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केन्द्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण को प्रतिपित्र करके विनियमित करना लोकहित में आवश्यक और समीचीन है;

अतः, अब, केन्द्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन सामग्री अधिनियम, 1940 (1940 का 23) की धारा 26 के अध्याय अधिकारों का प्रयोग करते हुए, लैवोसिट्रिज फेरॉनिफरीन + एम्ब्रोकोल + ग्वाइफेनिसिंस + पारासिटामॉल की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तत्काल प्रभाव से प्रतिपित्र करती है।

[फा. सं. एस्ट्र-11035/53/2014-डीईएफजी]
K. L. SHARMA, Jt. Secy.

NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 886(E)—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Levocetirizine + Phenylephrine + Ambroxol + Guaiphenesin + Paracetamol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Levocetirizine + Phenylephrine + Ambroxol + Guaiphenesin + Paracetamol with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
And whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Cetirizine + Dextromethorphan + Phenylephrine + Zinc Gluconate + Paracetamol + Menthol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country:

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Cetirizine + Dextromethorphan + Phenylephrine + Zinc Gluconate + Paracetamol + Menthol with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 888(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Paracetamol + Pseudoephedrine + Dextromethorphan + Cetirizine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Paracetamol + Pseudoephedrine + Dextromethorphan + Cetirizine with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 889(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Diphenhydramine + Guaiphenesin + Ammonium Chloride + Bromhexine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Diphenhydramine + Guaiphenesin + Ammonium Chloride + Bromhexine with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

बिहिसूचना

नई दिल्ली, 10 मार्च, 2016

का.आ. 890(अ).—केंद्रीय सरकार का यह समाधान हो गया है कि फ्लोकरेनिरामाइन + डेक्स्ट्रोमोरफेन + फ्लाइनैलफ़ेरीन + पेरासिटामोल की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन की खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षा अनुशंसा उपलब्ध हैं;

और इस विवाद की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि उक्त औषधि की सीधी औषधि नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण को प्रतिपिद्ध करके विनियमित करना लोकहित में आवश्यक और समीचीन है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन मामलों अधिनियम, 1940 (1940 का 23) की धारा 26 के द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, क्लोरकरेनाइन + डेक्स्ट्रोमोरफेन + फ्लाइनैलफेरीन + पेरासिटामोल की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तकनीकी प्रमाण से प्रतिपिद्ध करती है।

[फा. सं. एक्स-11035/53/2014-डीएफ़सी]
NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 890(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Chlorpheniramine + Dextromethorphan + Phenylephrine + Paracetamol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Chlorpheniramine + Dextromethorphan + Phenylephrine + Paracetamol with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

अधिसूचना
नई दिल्ली, 10 मार्च, 2016

का.आ. 891(म).—केंद्रीय सरकार का यह समाधान हो गया है कि डेक्सट्रोमथरफन + प्रोमेथाईजन की नियत खुराक संयोजन औषधि के प्रयोग में मानव जीवन की खतरा होने की संभावना है, तबकि उक्त औषधि के सुरक्षित अनुकूल उपयोग है;

इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जाँच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय आयुर्विज्ञान नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयवार्त विनिमय, विक्रय और वितरण की प्रतिपिप्दन करने विनियमित करना लोकहित में आवश्यक और सामीचीन है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन सामग्री अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त अंशियों का प्रयोग करते हुए, डेक्सट्रोमथरफन + प्रोमेथाईजन की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयवार्त विनिमय, विक्रय और वितरण तक्षाल प्रभाव में प्रतिपिप्दन करती है।

[फा. सं. एक्स-11035/53/2014-डीएफ्‌सी]
कुदन लाल शर्मा, सन्युक्त सचिव

NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 891(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Dextromethorphan + Promethazine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;
And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Dextromethorphen + Promethazine** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

**NOTIFICATION**

New Delhi, the 10th March, 2016

S.O. 892(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Diethylcarbamazine Citrate + Cetirizine + Guaiphenesin** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Dextromethorphen + Promethazine** with immediate effect.
hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Diethylcambamazine Citrate + Cetirizine + Guaiphenesin** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

### NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 893(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Pseudoephedrine + Dextromethorphan + Cetirizine** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Pseudoephedrine + Dextromethorphan + Cetirizine** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 894(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Chlorpheniramine + Phenylephrine + Dextromethophan + Menthol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Chlorpheniramine + Phenylephrine + Dextromethophan + Menthol with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
औषिध के केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विकिरणीय आंचल नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण को प्रतिपिठ करके विनियमित करना लोकतंत्र में आवश्यक और सामील रूप से,

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और उपचार मामलों अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, एम्ब्रोक्सोल + टेरबूटालाइन सल्फेट + डेक्स्ट्रोमेथोफेन डायड्रोब्रोमाइड का नियत खुराक संयोजन औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तकनीक प्रभाव से प्रतिपिठ करती है।

[फा. सं. एक्स-11035/53/2014-डीएफक्सी]

कुंदला लाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 895(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Ambroxol + Terbutaline + Dextromethorphan is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Ambroxol + Terbutaline + Dextromethorphan with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 896(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Dextromethorphan + Chlorpheniramine + Guaiphenesin is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Dextromethorphan + Chlorpheniramine + Guaiphenesin with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of the said drug with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 897(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Terbutaline + Bromhexine + Guaiphenesin + Dextromethorphan is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Terbutaline + Bromhexine + Guaiphenesin + Dextromethorphan with immediate effect.

[F. No. X-11035/53/2014-DFQC]
NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 898(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Dextromethorphan + Tripolidine + Phenylephirine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug Dextromethorphan + Tripolidine + Phenylephirine with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

अधिकृतेना
नई दिल्ली, 10 मार्च, 2016

का.श. 899(म)—केंद्रीय सरकार का यह समाधान हो गया है कि पेरास्टामोल +डेक्स्ट्रोमेथोरफ़न + ब्लोपरेफिनियामाइन की नियत खुराक संयोजन औषधि के प्रयोग में मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के मुख्यतः अनुकूल उपकर्ष हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विकल्पी औषधि नहीं हैं;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयवर्ष विमोचन, विक्रय और वितरण को प्रतिपिद्ध करके विनियमित करना लोकहिं हेतु आवश्यक और समीचित हैं;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन सामग्री अधिनियम, 1940 (1940 का 23) की धारा 26 का द्वारा प्रदत्त अधिकारियों का प्रयोग करते हुए, पेरास्टामोल +डेक्स्ट्रोमेथोरफ़न +ब्लोपरेफिनियामाइन की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयवर्ष विमोचन, विक्रय और वितरण तक्कल प्रभाव से प्रतिपिद्ध करती है।

[फा. सं. एस-11035/53/2014-डीएफसी]
कुंदल लाल शर्मा, संयुक्त सचिव

NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 899(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Paracetamol + Dextromethorphan + Chlorpheniramine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

[फा. सं. एस-11035/53/2014-डीएफसी]
Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Paracetamol + Dextromethorphan + Chlorpheniramine** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 900(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Pholcodine + Phenylephrine + Promethazine** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Pholcodine + Phenylephrine + Promethazine** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 901(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Codeine + Levocetirizine + Menthol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Codeine + Levocetirizine + Menthol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
अन्धिनयम, 1940 (1940 का 23)

सौष्ठव के मानव उपयोग के लिए

वर्तमान औषिध के द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केन्द्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विकिरणीय औषधि नहीं है।

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केन्द्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनियमान, विक्रय और वितरण की प्रतिपद्ध करके विनियमित करना लोकहित में आवश्यक और समीचीन है।

अतः, अब, केन्द्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन मामलों के अधिनियम, 1940 (1940 का 23) की धारा 26 के अनुसार शर्तों का प्रयोग करते हुए, डेक्स्ट्रोमेथोफ्यूरेन +एम्ब्रोक्सोल +गूआइफेलिन+पिनाइफेलीन +क्लोरपेनियाइन की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनियमान, विक्रय और वितरण तकलक व्रत्य से प्रतिपद्ध करती है।

[फा. सं. एफ़-11035/53/2014-टीएफ़थ्रूसी]

कुदं लाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 902(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Dextromethorphan + Ambroxol + Guaifenesin + Phenylephrine + Chlorpheniramine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Dextromethorphan + Ambroxol + Guaifenesin + Phenylephrine + Chlorpheniramine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अधिकृतमान

नई दिल्ली, 10 मार्च, 2016

का. आ 903(भ).—केन्द्रीय सरकार का यह समाधान हो गया है कि सिट्रीफ्लिन +फिनाइफ्लेरिन +डेक्स्ट्रोमेथोफ्यूरेन +मेथोल की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन की खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपप्रयोग हैं;

और इस विषय की केंद्रीय सरकार द्वारे नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केन्द्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विकिरणीय औषधि नहीं है।

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केन्द्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनियमान, विक्रय और वितरण की प्रतिपद्ध करके विनियमित करना लोकहित में आवश्यक और समीचीन है।
NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 903(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Cetirizine + Phenylephrine + Dextromethorphan + Menthol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government and the said Expert Committee recommended to the Central Government that the said drug is to be prohibited

New Delhi, 10th March, 2016

K. L. SHARMA, Jt. Secy.

[No. X-11035/53/2014-DFQC]
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 904(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Roxithromycin + Serratiopeptidase is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Roxithromycin + Serratiopeptidase with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 905(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Paracetamol + Phenylephrine + Triprolidine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;
And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Paracetamol + Phenylephrine + Tripolidine with immediate effect.

[F. No. X-11035/53/2014-DFQC]  
K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 906(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Acetaminophen + Loratadine + Ambroxol + Phenylephrine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Acetaminophen + Loratadine + Ambroxol + Phenylephrine with immediate effect.

[F. No. X-11035/53/2014-DFQC]  
K. L. SHARMA, Jt. Secy.
NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 907(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Cetirizine + Acetaminophen + Dextromethorphan + Phenytoin + Zinc Gluconate is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Cetirizine + Acetaminophen + Dextromethorphan + Phenytoin + Zinc Gluconate with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 908(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Diphenhydramine + Guaifenesin + Bromhexine + Ammonium Chloride + Menthol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Diphenhydramine + Guaifenesin + Bromhexine + Ammonium Chloride + Menthol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
AND WHEREAS, the Central Government is satisfied that the use of the drug fixed dose combination of Chlopheniramine Maleate + Codeine Syrup is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Chlopheniramine Maleate + Codeine Syrup with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016
S.O. 909(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Chlopheniramine Maleate + Codeine Syrup is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Chlopheniramine Maleate + Codeine Syrup with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016
S.O. 909(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Chlopheniramine Maleate + Codeine Syrup is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Chlopheniramine Maleate + Codeine Syrup with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016
S.O. 909(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Chlopheniramine Maleate + Codeine Syrup is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Chlopheniramine Maleate + Codeine Syrup with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 910(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Cetirizine + Dextromethorphan + Zinc Gluconate + Menthol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Cetirizine + Dextromethorphan + Zinc Gluconate + Menthol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 911(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Paracetamol + Phenylephrine + Desloratadine + Zinc Gluconate + Ambroxol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Paracetamol + Phenylephrine + Desloratadine + Zinc Gluconate + Ambroxol with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

विषयों दिन, 10 मार्च, 2016

का.आ. 912(व).—केंद्रीय सरकार का वह समाधान हो गया है कि लेवोसिटरिजिन + मोंटेलुकास्ट+एच्रोफिल्लिन की नियत मिश्रण संयोजन औषधि के प्रयोग में मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपलब्ध हैं;

और इस विषय की केंद्रीय सरकार द्वारा अनुकूल विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को वह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय अंशित नहीं है।

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विभिन्नरूप वितरण, विक्रय और वितरण की प्रतिष्ठा करने विनियमित करना लोकहित में आवश्यक और समीचीन हैं;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन सामग्री अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त शर्तों का प्रयोग करते हुए, लेवोसिटरिजिन + मोंटेलुकास्ट+एच्रोफिल्लिन की नियत मिश्रण संयोजन औषधि का मानव उपयोग के लिए विभिन्नरूप वितरण, विक्रय और वितरण तत्काल प्रभाव से प्रतिष्ठा करती है।

[फा. म. एक्स-11035/53/2014-डीएफसी]  
कृपया लाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 912(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Levocetirizine + Montelukast + Acebrophylline is likely to involve risk to human beings whereas safer alternatives to the said drug are available;
And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Levocetirizine + Montelukast + Acebrophylline with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 913(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Dextromethorphan + Phenylephrine + Ammonium Chloride + Menthol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government...
hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Dextromethorphan + Phenylephrine + Ammonium Chloride + Menthol with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 914(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Dextromethorphan + Bromhexine + Guaiphenesin + Menthol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Dextromethorphan + Bromhexine + Guaiphenesin + Menthol with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 915(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Acrivastine + Paracetamol + Caffeine + Phenylephrine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Acrivastine + Paracetamol + Caffeine + Phenylephrine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विकितनी औषधि नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विद्यमान, विक्रय और वितरण को प्रतिष्ठित करके विनियमित करना लोकहिंत में आवश्यक और समीचीन है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन मामली अधिनियम, 1940 (1940 का 23) की धारा 26A द्वारा प्रदत्त अधिकार का प्रयोग करते हुए, नेफाज़ोलीन +कार्बोक्सी विथाइल सेलुलोस +मेंटोल +काम्फर +फिनाइलेफरीन नेफाज़ोलीन +मेंटोल +काम्फर +फिनाइलेफरीन की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विद्यमान, विक्रय और वितरण तत्त्वक प्रभाव से प्रतिष्ठित करती है।

[फा. सं. एक्स-11035/53/2014-डीएफ्सी]
कुदन लाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 916(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Naphazoline + Carboxy Methyl Cellulose + Menthol + Camphor + Phenylephrine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Naphazoline + Carboxy Methyl Cellulose + Menthol + Camphor + Phenylephrine with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

अधिसूचना

नई दिल्ली, 10 मार्च, 2016

का.अ. 917(भ).—केंद्रीय सरकार का यह समाधान हो गया है कि डेस्ट्रॉमेोलोजन +स्ट्रॉमिलियन की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के मुश्किल अनुकूल प्रयोग है;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विकितनी औषधि नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विद्यमान, विक्रय और वितरण को प्रतिष्ठित करके विनियमित करना लोकहिंत में आवश्यक और समीचीन है;
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 917(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Dextromethorphan + Cetirizine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country:

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Dextromethorphan + Cetirizine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

विविधसूचना

नई दिल्ली, 10 मार्च, 2016

क.आ.918(ब).—केंद्रीय सरकार का यह समाधान हो गया है कि निमेश्वुलाइड + पैरासिटामोल+सेतिरिझिन +फिनाइफ्लॉरिन +कैफिन की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन की खतरा होने की संभावना है, जबकि उक्त औषधि के गुणधर्म अनुकूल उपलब्ध हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जोने की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई भिन्नीय अवधि नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थी विनिमय, विक्रय और वितरण को प्रतिपिद्ध करने के विनिमय करना लोकशाही में आवश्यक और समीचीन है;

अतः, अव, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन सामग्री अधिनियम, 1940 (1940 का 23) की धारा 26 के तहत शक्तियां का प्रयोग करते हुए, निमेश्वुलाइड + पैरासिटामोल + फिनाइफ्लॉरिन +कैफिन की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थी विनिमय, विक्रय और वितरण तत्काल प्रभाव से प्रतिपिद्ध करती है।

[फा. सं. एक्स-11035/53/2014-डीएफसी]]

कुदंद लाल शर्मा, संयुक्त सचिव
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 918(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Nimesulide + Paracetamol + Levocetirizine + Phenylephrine + Caffeine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Nimesulide + Paracetamol + Levocetirizine + Phenylephrine + Caffeine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 919(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Terbutaline + Ambroxol + Guaiaphenesin + Zinc + Menthol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;
Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Terbutaline + Ambroxol + Guaiphenesin + Zinc + Menthol** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

### NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 920(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Codeine + Chlorpheniramine + Alcohol Syrup** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Codeine + Chlorpheniramine + Alcohol Syrup** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 921(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Dextromethorphan + Phenylephrine + Guaifenesin + Triprolidine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Dextromethorphan + Phenylephrine + Guaifenesin + Triprolidine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 922(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Ammonium Chloride + Bromhexine + Dextromethorphan is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Ammonium Chloride + Bromhexine + Dextromethorphan with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

काशीकृति

नई दिल्ली, 10 मार्च, 2016

कान. 923(अ).—केंद्रीय सरकार का यह समाधान हो गया है कि ड्राइव्हेलार्क्सेमिज, +सिट्रेलिन + एम्ब्रॉक्साइल की नियत खुराक संयोजन औषधि के प्रयोग में मानव जीवन की खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपयोग हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई सिस्टेमिक ध्वस्त नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमयाण, वित्राश्रय और वितरण को प्रतिपिप्त करके विनियमित करना लोकहित में आवश्यक और समीचीन है;
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 923(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Diethylcarbamazine + Cetirizine + Ambroxol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Diethylcarbamazine + Cetirizine + Ambroxol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 924(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Ethylmorphine + Noscapine + Chlorpheniramine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Ethylmorphine + Noscapine + Chlorpheniramine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अधिसूचना

नई दिल्ली, 10 मार्च, 2016

कार्य. 925(ब).—केंद्रीय सरकार का यह समाधान हो गया है कि सिमित ने त्रेरापी + डेक्स्ट्रोमेथोपरफेन + एम्ब्रोक्लोल की निवित खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपलब्ध हैं;

और इस विषय के केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जोड़ की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिचा की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विकिरणीय औषधित्व नहीं है;

और उक्त विशेषज्ञ समिति की सिचवियों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण को प्रतिपित्त करके विनियमित करना लोकहित में आवश्यक और समीचित है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिचवियों के आधार पर और औषधि और प्रसाधन सामग्री अधिनियम, 1940 (1940 का 23) की धारा 28क द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, सिमित ने त्रेरापी + डेक्स्ट्रोमेथोपरफेन + एम्ब्रोक्लोल की निवित खुराक संयोजन औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तक्तक प्रभाव से प्रतिपित्त करती है।

[फा. सं. एक्स-11035/53/2014-डीएफ्पीसी]

कुलद लाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 925(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Cetirizine + Dextromethorphan + Ambroxol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;
And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Cetirizine + Dextromethorphan + Ambroxol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 926(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Bromhexine + Dextromethorphan + Ammonium Chloride + Menthol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Bromhexine + Dextromethorphan + Ammonium Chloride + Menthol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 827(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Ambroxol + Guaifenesin + Phenylephrine + Chlorpheniramine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Ambroxol + Guaifenesin + Phenylephrine + Chlorpheniramine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 928(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Paracetamol + Phenylephrine + Chlorpheniramine + Zinc Gluconate is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Paracetamol + Phenylephrine + Chlorpheniramine + Zinc Gluconate with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government. Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Dextromethorphan + Phenylephrine + Cetirizine + Paracetamol + Caffeine with immediate effect.

[F. No. X-11035/53/2014-DFQC]  
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 930(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Dextromethorphan + Chlorpheniramine + Guaifenesin + Ammonium Chloride is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose Dextromethorphan + Chlorpheniramine + Guaifenesin + Ammonium Chloride with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 931(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Levocetirizine + Dextromethorphan + Zinc is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Levocetirizine + Dextromethorphan + Zinc with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 932(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Paracetamol + Phenylephrine + Levocetirizine + Caffeine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Paracetamol + Phenylephrine + Levocetirizine + Caffeine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

नई दिल्ली, 10 मार्च, 2016

का.व.ा. 933(०)—केंद्रीय सरकार का यह समाधान हो गया है कि क्लोरफेनिरामाइन + अमोनियम + क्लोराइड + सोडियम क्लोराइड की नियम खुराक संयोजन औषधि के प्रयोग के मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के मुख्य अनुकूल उपयोग है;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सुनिश्चित की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विचित्र औषधि नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण को प्रतिपिठ करके विनियमित करना लोकप्रिय में आवश्यक और समीचीन है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और आवश्यक और प्रमाणित मामलों के अधिनियम, 1940 (1940 का 23) की धारा 26क हाँ के दर्जन उन्मत्तियों का प्रयोग करते हुए, क्लोरफेनिरामाइन + अमोनियम + क्लोराइड + सोडियम क्लोराइड की नियम खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तक्तक प्रभाव में प्रतिपिठ करती है।

[फा. सं. एक्स-11035/53/2014-कीएफसी]  
कुंदल लाल शर्मा, संयुक्त सचिव
NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 933(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Chlorpharniramime + Ammonium Chloride + Sodium Chloride** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition fixed dose combination of Chlorpharniramime + Ammonium Chloride + Sodium Chloride with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 934(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Paracetamol + Dextromethorphan + Bromhexine + Phenylephrine + Diphenhydramine** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;
And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Paracetamol + Dextromethorphan + Bromhexine + Phenylephrine + Diphenhydramine** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 935(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Salbutamol + Bromhexine + Guaiphenesin + Menthol** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;
And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Salbutamol + Bromhexine + Guaiphenesin + Menthol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 936(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Chlorpheniramine + Ammonium Chloride + Nocapine + Sodium Citrate is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Chlorpheniramine + Ammonium Chloride + Nocapine + Sodium Citrate with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 937(E)—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Cetirizine + Dextromethorphan + Bromhexine + Guaifenesin** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Cetirizine + Dextromethorphan + Bromhexine + Guaifenesin** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 938(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Diethyl Carbamazine + Chlorpheniramine + Guaifenesin** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Diethyl Carbamazine + Chlorpheniramine + Guaifenesin** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अधिकृत

नई दिल्ली, 10 मार्च, 2016

कार्यकारिणी, 939(III)—राज्य सरकार का यह समाधान हो गया है कि केटोफेन + चिल्पिन की नियत खुराक संयोजन शैली के प्रयोग से मानव जीवन को खतरा होने की समाप्ति है, जबकि उक्त अवधि के सुधार के अनुकूल उपचार है;

और इस विषय की राज्य सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने राज्य सरकार की यह समस्या की है कि उक्त अवधि के बारे में यह पाया गया है कि इसका कोई विशेषज्ञ शैली नहीं है;

और उक्त विशेषज्ञ समिति की समस्या के आधार पर राज्य सरकार का यह समाधान हो गया है कि देश में उक्त अवधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण को प्रतिपादित करने विनियमित करना लोकतंत्र में आवश्यक और समीचीन है।
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 939(E).—Whereas, the Central Government is satisfied that the use of the drug *fixed dose combination of Ketotifen + Cetirizine* is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug *fixed dose combination of Ketotifen + Cetirizine* with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 940(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Terbutaline + Bromhexine + Etofylline is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Terbutaline + Bromhexine + Etofylline with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 941(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Ketotifen + Theophylline is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;
And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug \textit{fixed dose combination of Ketotifen + Theophylline} with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

\textbf{NOTIFICATION}

New Delhi, the 10th March, 2016

\textbf{S.O. 942(E).}—Whereas, the Central Government is satisfied that the use of the drug \textit{fixed dose combination of Ambroxol + Salbutamol + Theophylline} is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug \textit{fixed dose combination of Ambroxol + Salbutamol + Theophylline} with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 943(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Cetirizine + Nimesulide + Phenylephrine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Cetirizine + Nimesulide + Phenylephrine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 944(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Chlorpheniramine + Phenylephrine + Paracetamol + Zink Gluconate** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination Chlorpheniramine + Phenylephrine + Paracetamol + Zink Gluconate** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अधिसूचना

नई दिल्ली, 10 मार्च, 2016

क.श. 945(ब)—केंद्रीय सरकार का यह समाधान हो गया है कि **एसिटामिनोफेल + सुब्स्ट्रॉफेल + क्लोरफेनिराइड** की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन की खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपलब्ध हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सूचित की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विभिन्न अधिक नहीं हैं;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण को प्रतिपिप्द करके विनिमय कर्ता लोकगत में आश्वस्त और समीक्षीय हैं;

अत: अत: केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन समाध्री अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, **एसिटामिनोफेल + सुब्स्ट्रॉफेल + क्लोरफेनिराइड** की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तत्काल प्रभाव में प्रतिपिप्द करती है।

[फा. सं. एससे-11035/53/2014-कीएफकूडी]
NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 945(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Acetaminophen + Guaifenesin + Dextromethorphan + Chlorpheniramine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Acetaminophen + Guaifenesin + Dextromethorphan + Chlorpheniramine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 946(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Cetirizine + Dextromethorphan + Phenylephrine + Tulsi is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;
And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Cetirizine + Dextromethorphan + Phenylephrine + Tulsi** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 947(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Cetirizine + Phenylephrine + Paracetamol + Ambroxol + Caffeine** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Cetirizine + Phenylephrine + Paracetamol + Ambroxol + Caffeine** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 948(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Guaifenesin + Dextromethorphan is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Guaifenesin + Dextromethorphan with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण की प्रतिपिद्ध करके विनिमयित करना लोकक्रिया में आवश्यक और सर्वसाधारण है;

अतः अन्तर्गत, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन समूह के अधिनियम, 1940 (1940 का 23) की धारा 26 के तहत विशेष अवधारणा का प्रयोग करते हुए, लेवोसिटिरिजिन + पैरासिटामोल + फिलाइफेरिन + कैफीन की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तकलीफ प्रभाव से प्रतिपिद्ध करती है।

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 949(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Levocetirizine + Paracetamol + Phenylephrine + Caffeine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Levocetirizine + Paracetamol + Phenylephrine + Caffeine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अधिसूचना

नई दिल्ली, 10 मार्च, 2016

का.आ. 950(म)—केंद्रीय सरकार का यह समाधान हो गया है कि कैफीन + पैरासिटामोल + फिलाइफेरिन + क्लोरफेफेटामाइन की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन की खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपयोग है;

और इस विषय के केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की हैं कि उक्त औषधि के बार में यह पाया गया है कि इसका कोई चिकित्सात्मक अधिकार नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण की प्रतिपिद्ध करके विनिमयित करना लोकक्रिया में आवश्यक और सर्वसाधारण है;

अतः, अन्तर्गत, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन समूह के अधिनियम, 1940 (1940 का 23) की धारा 26 के तहत विशेष अवधारणा का प्रयोग करते हुए, कैफीन + पैरासिटामोल + फिलाइफेरिन + क्लोरफेफेटामाइन की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तकलीफ प्रभाव से प्रतिपिद्ध करती है।

[फ. सं. एससु. 11035/53/2014-डीएफसी]
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 950(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Caffeine + Paracetamol + Phenylephrine + Chlorpheniramine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Caffeine + Paracetamol + Phenylephrine + Chlorpheniramine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

नई दिल्ली, 10 मार्च, 2016

का.आ. 951(ब).—केंद्रीय सरकार का यह समाधान हो गया है कि के́टोटीफेन + ल्येरोट्रिशिन की नियत खूराक संयोजन औषध के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषध के सुरक्षित अनुकूल उपलब्ध है;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषध के बारे में यह पारा गया है कि इसका कोई चिकित्सकीय जितना नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषध के मानने उपयोग के लिए विक्रयार्थ विनिमयां, विक्रय और वितरण को प्रतिपिपिद करके विनियमित करना लोकहित में आवश्यक और समीचीन है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषध और प्रसारण समग्री अधिनियम, 1940 (1940 का 23) की धारा 26(क) द्वारा प्रदत्त अनुदेशों का प्रयोग करते हुए, के́टोटीफेन + ल्येरोट्रिशिन की नियत खूराक संयोजन औषध का मानने उपयोग के लिए विक्रयार्थ विनिमयां, विक्रय और वितरण तक्ताल प्राप्त होने से प्रतिपिपिद करती है।

[फा. सं. एस्स-11035/53/2014-डीएफ़सी]

कृंदन लाल शर्मा, संयुक्त सचिव
And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Ketotifen + Levocetrizine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अधिसूचना

नई दिल्ली, 10 मार्च, 2016

फा. नं. 952(ि)—केन्द्रीय सरकार का यह समाधान हो गया है कि परासिटामोल + लेवोसिट्रिनिन + फिनाइलर्फीन + जिंक स्लुक्वेनेट की नियमित खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपलब्ध हैं;

और इस विषय के केन्द्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केन्द्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि उक्त औषधि की सीमित औषधि नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशें के आधार पर केन्द्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण को प्रतिपिष्ट करने विनियमित करना लोकहित में आवश्यक और समीचीन है;

अतः, अब, केन्द्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशें के आधार पर और औषधि और प्रसाधन मामले अधिनियम, 1940 (1940 का 23) की धारा 26के द्वारा प्रदत्त शक्तियाँ का प्रयोग करते हुए, परासिटामोल + लेवोसिट्रिनिन + फिनाइलर्फीन + जिंक स्लुक्वेनेट की नियमित खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तत्काल प्रभाव से प्रतिपिष्ट करती है।

[फा. सं. एस्स-11035/53/2014-कीएफूसी]

कुंदन लाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 952(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Paracetamol + Levocetrizine + Phenyphrine + Zink Gluconate is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;
Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Paracetamol + Levocetirizine + Phenylephrine + Zink Gluconate** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 953(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Paracetamol + Phenylephrine + Triprolidine + Caffeine** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Paracetamol + Phenylephrine + Triprolidine + Caffeine** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 954(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Caffeine + Paracetamol + Phenylephrine + Cetirizine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Caffeine + Paracetamol + Phenylephrine + Cetirizine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 963(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Caffeine + Paracetamol + Chlorpheniramine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Caffeine + Paracetamol + Chlorpheniramine with immediate effect.

[F. No. X-11035/53/2014-DFQC.]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 964(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Ammonium Chloride + Dextromethorphan + Cetirizine + Menthol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Ammonium Chloride + Dextromethorphan + Cetirizine + Menthol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अधिसूचना

नई दिल्ली, 10 मार्च, 2016

का.शा. 965(ए)—केंद्रीय सरकार का यह समाधान हो गया है कि डीस्ट्रोमेथोर्फर्फर + पैरासिटोमोल + सिट्रीजिन + मेंथोल की नियत खुराक संयोजन ओप्शन के प्रयोग में मानव जीवन को खतरा होने की संभावना है, जबकि उक्त ओप्शन के सम्भावित अनुकूल उपलब्ध हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त ओप्शन के बारे में यह पाया गया है कि इसका कोई चिकित्सीय आवश्यक नहीं है;
और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औपचारिक मानव उपयोग के लिए विक्रयार्थ विनिमयान, विक्रय और वितरण को प्रतिपिप्ठ करके विनियमित करना लोकत्रिप में आवश्यक और सामीचीन हैं;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औपचारिक और स्वाभाविक नियन्त्रण 1940 (1940 का 23 जीवन को खतरा हो) 26 द्वारा प्रदत्त उक्तियों का प्रयोग करते हुए, डेक्स्ट्रोमेथोर्फाइन + पैराइस्टोराइन + सिट्रिनिन + फिलाइफेयरिन की नियत खुराक संयोजन औपचारिक मानव उपयोग के लिए विक्रयार्थ विनिमयान, विक्रय और वितरण तक्काल प्रभाव से प्रतिपिप्ठ करती है।

[फा. सं. एक्स-11035/53/2014-डीएफसी]
कुंदन लाल शर्मा, संयुक्त सचिव

NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 965(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Dextromethorphan + Paracetamol + Cetirizine + Phenylephrine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Dextromethorphan + Paracetamol + Cetirizine + Phenylephrine with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 966(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Chlorpheniramine + Terpin + Antimony Potassium Tartrate + Ammonium Chloride + Sodium Citrate + Menthol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Chlorpheniramine + Terpin + Antimony Potassium Tartrate + Ammonium Chloride + Sodium Citrate + Menthol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
ौर इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विज्ञानीय औषधि नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमयां, विक्रय और वितरण को प्रतिपित्र करके विनियमित करना लोकहित में आवश्यक और समीचीन है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन सामग्री अधिनियम, 1940 (1940 का 23) की धारा 26 के द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, टेरबुटालाइन + इटोफाइलिन + एम्ब्रोक्सोल की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमयां, विक्रय और वितरण तत्काल प्रभाव से प्रतिपित्र करती है।

[फा. सं. एक्स-11035/53/2014-डीएफजीसी]
कुंदल लल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 967(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Terbutaline + Etofylline + Ambroxol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Terbutaline + Etofylline + Ambroxol with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

अधिसूचना

नई दिल्ली, 10 मार्च, 2016

का.आ. 968(ज)—केंद्रीय सरकार का यह समाधान हो गया है कि पैरातिस्टामोल + कोडीन + क्लोरफ़ेनिनाइन की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकल्प उपलब्ध हैं;
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 968(E).— Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Paracetamol + Codeine + Chlorpheniramine** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Paracetamol + Codeine + Chlorpheniramine** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
अधिसूचना

नई दिल्ली, 10 मार्च, 2016

का.श. 969(ब)—केंद्रीय सरकार का यह समाधान हो गया है कि पैरासिटामोल +स्यूडोफेरेड्रिन+सिटरिजिन+कैफीन की नियत भुरक संयोजन औपचारिक प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औपचारिक सुरक्षित अनुकूल उपलब्ध हैं।

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जोध की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औपचारिक के बारे में यह पाया गया है कि इसका कोई चिकित्सीय अधिकार नहीं है।

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औपचारिक के मानव उपयोग के लिए विक्रयार्थ विनिमयान, विक्रय और वितरण को प्रतिष्ठित करके विनियमित करना लोकहित में आवश्यक और समीचीन है।

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औपचारिक और प्रसाधन सामग्री अधिनियम, 1940 (1940 का 23) की धारा 26 के द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, पैरासिटामोल +स्यूडोफेरेड्रिन+सिटरिजिन+कैफीन की नियत भुरक संयोजन औपचारिक मानव उपयोग के लिए विक्रयार्थ विनिमयान, विक्रय और वितरण तकाल प्रभाव से प्रतिष्ठित करती है।

[फा. सं. एक्स-11035/53/2014-डीएफजीसी]

कुलदत्त लाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 969(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Paracetamol+Pseudoephedrine+Cetirizine+Caffeine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Paracetamol+Pseudoephedrine+Cetirizine+Caffeine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 970(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Chlorpheniramine+Ammonium Chloride + Menthol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Chlorpheniramine+Ammonium Chloride + Menthol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 971(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of N-Acetyl Cysteine + Ambroxol + Phenylephrine + Levocetirizine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of N-Acetyl Cysteine + Ambroxol + Phenylephrine + Levocetirizine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 972(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Dextromethorphan + Phenylephrine + Tripolidine + Menthol** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Dextromethorphan + Phenylephrine + Tripolidine + Menthol** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 973(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Salbutamol + Certirizine + Ambroxol** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;
Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Salbutamol + Cetirizine + Ambroxol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 974(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Dextromethorphan + Phenylephrine + Bromhexine + Guaifenesin + Chlorpheniramine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Dextromethorphan + Phenylephrine + Bromhexine + Guaifenesin + Chlorpheniramine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 975(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Nimesulide + Certirizine + Phenylephrine** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Nimesulide + Certirizine + Phenylephrine** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अभियुक्त

नई दिल्ली, 10 मार्च, 2016

का.आ. 975(ए)—केन्द्रीय सरकार का यह समाधान हो गया है कि **निमेसुलाइड + सिपरित्रिनिफाइरिन + फिनाइफ्लरिन** की नियम खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल्य उपलब्ध हैं;

और इस विषय की केन्द्रीय सरकार द्वारा नियुक्त विषयक विभाग सभित द्वारा जांच की गई है और उक्त विदेशी विभाग सभित ने केन्द्रीय सरकार को यह साफ़ की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विचित्रित औषधि नहीं है;

और उक्त विदेशी विभाग सभित की साफ़ शिफरियों के आधार पर केन्द्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विविध विभिन्न विभागों, विक्रय और वितरण को प्रतिपद्ध करके विचित्रित करना लोकहित में आवश्यक और समीचीन है.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 976(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Naphazoline + Chlorpheniramine + Zinc Sulphate + Boric Acid + Sodium Chloride + Chlorobutol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Naphazoline + Chlorpheniramine + Zinc Sulphate + Boric Acid + Sodium Chloride + Chlorobutol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 977(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Paracetamol + Bromhexine + Phenylephrine + Chlorpheniramine + Guaifenesin is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Paracetamol + Bromhexine + Phenylephrine + Chlorpheniramine + Guaifenesin with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अधिसूचना

नई दिल्ली, 10 मार्च, 2016

फा.सं. एस-11035/53/2014-डीएफसी]

बंद हुए, शार्मा, मंत्री सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 978(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Salbutamol + Bromhexine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And whereas, it is likely that the said drug is found to have no therapeutic justification;
And whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Salbutamol + Bromhexine** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

---

**NOTIFICATION**

New Delhi, the 10th March, 2016

S.O. 979(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Dextromethorphan + Phenylephrine + Guaifenesin + Certirizine + Acetaminophen** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Dextromethorphan + Phenylephrine + Guaifenesin + Certirizine + Acetaminophen** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 980(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Guaifenesin + Bromhexine + Chlorpheniramine + Paracetamol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Guaifenesin + Bromhexine + Chlorpheniramine + Paracetamol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 981(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Chlorpheniramine + Ammonium Chloride + Chloroform + Menthol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Chlorpheniramine + Ammonium Chloride + Chloroform + Menthol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 982(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Salbutamol + Choline Theophyllinate + Ambroxol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Salbutamol + Choline Theophyllinate + Ambroxol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 983(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Chlorpheniramine + Codeine Phosphate + Menthol Syrup is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;
Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Chlorpheniramine + Codeine Phosphate + Menthol Syrup** with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

**NOTIFICATION**

New Delhi, the 10th March, 2016

S.O. 984(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Pseudoephedrine + Bromhexine** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Pseudoephedrine + Bromhexine** with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 985(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Certirizine + Phenylephrine + Paracetamol + Caffeine + Nimesulide is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Certirizine + Phenylephrine + Paracetamol + Caffeine + Nimesulide with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 986(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Dextromethorphan + Cetirizine + Guaifenesin + Ammonium Chloride is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Dextromethorphan + Cetirizine + Guaifenesin + Ammonium Chloride with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 987(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Ambroxol + Salbutamol + Choline Theophyllinate + Menthol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Ambroxol + Salbutamol + Choline Theophyllinate + Menthol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Paracetamol + Chlorpheniramine + Ambroxol + Guaifenesin + Phenylephrine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 989(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Chlorpheniramine + Vasaka + Toulubalsm + Ammonium Chloride + Sodium Citrate + Menthol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Chlorpheniramine + Vasaka + Toulubalsm + Ammonium Chloride + Sodium Citrate + Menthol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 990(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Bromhexine + Cetrizine + Phenylephrine IP + Guaifenesin + Menthol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Bromhexine + Cetrizine + Phenylephrine IP + Guaifenesin + Menthol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 991(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Dextromethorphan + Ambroxol + Ammonium Chloride + Chlorpheniramine + Menthol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Dextromethorphan + Ambroxol + Ammonium Chloride + Chlorpheniramine + Menthol with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

अधिसूचना

नई दिल्ली, 10 मार्च, 2016

का. आ. 992(अ)—केंद्रीय सरकार का यह समाधान हो गया है कि देक्स्ट्रोमेथॉर्फाइन फिनाइलफरीन + सिट्रीड्रिजिन + सिट्रीड्रिजिन + जिक + मेथेयल की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपयोग हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विषयक समिति द्वारा जांच की गई है और उक्त विषयक समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय आश्चर्य नहीं है;

और उक्त विषयक समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देखि में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण की प्रतिष्ठा करके विनियमित करना लोकहित में आवश्यक और समीचीन है;

अतः, अब, केंद्रीय सरकार, उक्त विषयक समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन समीचीन अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, देक्स्ट्रोमेथॉर्फाइन फिनाइलफरीन + सिट्रीड्रिजिन + सिट्रीड्रिजिन + जिक + मेथेयल की नियत खुराक संयोजन औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तक्कल प्रभाव से प्रतिष्ठा करती है।

[फ. नं. एस-11035/53/2014-कीएक्सवी]  
कुंदन लाल शर्मा, संयुक्त सचिव
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 992(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Dextromethorphan + Phenylephrine + Cetirizine + Zinc + Menthol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that the use of the drug is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Dextromethorphan + Phenylephrine + Cetirizine + Zinc + Menthol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अभियुक्त

नई दिल्ली, 10 मार्च, 2016

का.आ. 993(अ).—केन्द्रीय सरकार का यह समाधान हो गया है कि टेरबूटाइल्न + एन एसिटिल एल सिस्टिन + गुआइफेनेसिन की नियत युराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपलब्ध है;

और इस विषय की केन्द्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केन्द्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विकृतिस्वरूप औषधि नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केन्द्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण को प्रतिपिद्ध करके विनियमित करना लोकतंत्र में आवश्यक और समावेश्य है;

अत: अत: केन्द्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रमाणण मामले अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त शक्तियाँ का प्रयोग करते हुए, टेरबूटाइल्न + एन एसिटिल एल सिस्टिन + गुआइफेनेसिन की नियत युराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तलकाल प्रभाव से प्रतिपिद्ध करती है।

[फा. स. एस्स.एस्स-11035/53/2014-डीएफएफसी]

कुंदल लाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 993(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Terbutaline + N-Acetyl L-Cysteine + Guaifenesin is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;
Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Terbutaline + N-Acetyl L-Cysteine + Guaifenesin with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 994(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Calcium Gluconate + Levocetirizine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Calcium Gluconate + Levocetirizine with immediate effect.

[F. No. X 11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 995(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Paracetamol + Levoceitizine + Pseudoephedrine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Paracetamol + Levoceitizine + Pseudoephedrine with immediate effect.

[F. No. X 11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 996(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Salbutamol + Choline Theophyllinate + Carboctesteine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Salbutamol + Choline Theophyllinate + Carbocisteine with immediate effect.

[F. No. X 11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 997(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Chlorpheniramine + Vitamin C is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Chlorpheniramine + Vitamin C with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अवधिसूचना

नई दिल्ली, 10 मार्च, 2016

फा. अं. 998(अ).—केन्द्रीय सरकार का यह समाधान हो गया है कि फ्रेशियम स्क्लोकोबोट + क्लोरफेनिरामिन + विटामिन सी की नियम खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपलब्ध हैं;

और इस विषय के केन्द्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केन्द्रीय सरकार को यह सूचना की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विभिन्न औषधि नहीं है;

और उक्त विशेषज्ञ समिति की सूचनाओं के आधार पर केन्द्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमयां, विक्रय और वितरण को प्रतिपिठ करके विनियमित करना लोकतंत्र में आवश्यक और समीचीन है;

अतः, अब, केन्द्रीय सरकार, उक्त विशेषज्ञ समिति की सूचनाओं के आधार पर और औषधि और प्रभावकारण नामग्री अधिनियम, 1940 (1940 का 23) की धारा 26के द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, फ्रेशियम स्क्लोकोबोट + क्लोरफेनिरामिन + विटामिन सी की नियम खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमयां, विक्रय और वितरण तत्काल प्रभाव से प्रतिपिठ करती है।

[फा. सं. एक्स-11035/53/2014-कोलोफूर्मी]

कुंदन लाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 998(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Calcium Gluonate + Chlorpheniramine + Vitamin C is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;
Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Calcium Gluconate + Chlorpheniramine + Vitamin C** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 999(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Chlorpheniramine + Paracetamol + Pseudoephedrine + Caffeine** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Chlorpheniramine + Paracetamol + Pseudoephedrine + Caffeine** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1000(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Guaifenesin + Bromhexine + Chlorpheniramine + Phenylephrine + Paracetamol + Serratiopeptidase (as enteric coated granules) 10000 SP Units is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination
of Guaifenesin + Bromhexine + Chlorpheniramine + Phenylephrine + Paracetamol + Serratiopeptidase (as enteric coated granules) 10000 SP Units with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 1001(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Paracetamol + Pheniramine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Paracetamol + Pheniramine with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1002(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Betamethasone + Fusidic Acid + Gentamycin + Tolaftate + lodochlorhydroxyquinoline (ICHQ) is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Betamethasone + Fusidic Acid + Gentamycin + Tolaftate + lodochlorhydroxyquinoline (ICHQ) with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार की यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई सिद्धांतीय आवश्यक नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमयांग, विक्रय और वितरण को प्रतिपिप्त करके विनियमित करना लोकहित में आवश्यक और समीचीन है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसारण मामले अधिनियम, 1940 (1940 का 23) की धारा 26 का 26क वर्ग द्वारा ग्रस्त मामलों का प्रयोग करने हुए, क्लोबेतासोल + ओफ्लोक्साइन + माइकोनाजोल + जिक सल्फेट की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमयांग, विक्रय और वितरण तत्काल प्रभाव से प्रतिपिप्त करती है।

[फ. न. एक्स-11035/53/2014-डीएफजीसी]
कुंदन लाल शर्मा, मंत्री सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1003(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Clobetasol + Ofloxacin + Miconazole + Zinc Sulphate is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Clobetasol + Ofloxacin + Miconazole + Zinc Sulphate with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

अधिसूचना

नई दिल्ली, 10 मार्च, 2016

का.आ. 1004(A).—केंद्रीय सरकार का यह समाधान हो गया है कि क्लोबेतासोल + जेटामाइक्सिन + माइकोनाजोल + जिक सल्फेट की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपयोग है;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार की यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई सिद्धांतीय आवश्यक नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमयांग, विक्रय और वितरण को प्रतिपिप्त करके विनियमित करना लोकहित में आवश्यक और समीचीन है;
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1004(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Clobetasole + Gentamicin + Miconazole + Zinc Sulphate** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Clobetasole + Gentamicin + Miconazole + Zinc Sulphate** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अधिसूचना

नई दिल्ली, 10 मार्च, 2016

का.आ. 1005(अ)---केंद्रीय सरकार का यह समाधान हो गया है कि लेवोसिल्किंजन + एपासिटामोल + फिजिल्फिंगिन + परेसिटामोल की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है,

जबकि उक्त औषधि के सुरक्षित अनुकूल उपलब्ध हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विषयक समिति का ज्ञान की गई है और उक्त विषयक समिति ने केंद्रीय सरकार को यह सूचना की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय अधिकार नहीं है;

और उक्त विषयक समिति की सूचनाओं के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण को प्रतिपिठ करके विनिमयित करना लोकहत्त्र में आवश्यक और समीचीन है;

अतः, अब, केंद्रीय सरकार, उक्त विषयक समिति की सूचनाओं के आधार पर और औषधि और प्रसाधन समग्री अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, लेवोसिल्किंजन + एपासिटामोल + फिजिल्फिंगिन + परेसिटामोल की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तत्काल प्रभाव से प्रतिपिठ करती हैं।

[फ. स. एक्स-11035/53/2014-दीएफसी]
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1005(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Levocetirizine + Ambroxol + Phenylephrine + Paracetamol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Levocetirizine + Ambroxol + Phenylephrine + Paracetamol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अधिसूचना

नई दिल्ली, 10 मार्च, 2016

कार्यवाहक, 1006(ब).—केंद्रीय सरकार का यह समाधान हो गया है कि परमेथ्रिन + सेट्रिमाइड + मेंथोल की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के गुरुत्वात्मक अनुक्रम उपलब्ध हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विकिरणीय औषधियत नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमयाण, विक्रय और वितरण को प्रतिपिप्द्व करके विनियमित करना लोपकार में आवश्यक और समीचीन है;

अत:, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसारण सामग्री अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, परमेथ्रिन + सेट्रिमाइड + मेंथोल की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमयाण, विक्रय और वितरण तकाल प्रभाव से प्रतिपिप्द्व करती है।

[फ. न. एक्स-11035/53/2014-दीएफ्सी]

कुंदन लाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1006(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Permethrin + Cetrimide + Menthol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;
And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Permethrin + Cetrimide + Menthol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1007(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Beclomethasone + Clotimazole + Neomycin + Iodochlorohydroxyquinone is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government
hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Beclomethasone + Clotimazole + Neomycin + Iodochlorhydroxyquinone with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1008(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Neomycin + Doxycycline is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Neomycin + Doxycycline with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1009(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Ciprofloxacin + Fluconolone + Clotrimazole + Neomycin + Chlorocresol is likely to involve risk to human beings whereas safer alternatives to the said drug are available; And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification; And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country; Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Ciprofloxacin + Fluconolone + Clotrimazole + Neomycin + Chlorocresol with immediate effect.

[F. No. X-11035/53/2014-DFQC]  
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1010(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Clobetasol + Ofloxacin + Ketoconazol + Zinc Sulphate is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Clobetasol + Ofloxacin + Ketoconazol + Zinc Sulphate with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
अतः अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन मामले
अधिनियम, 1940 (1940 का 23) की धारा 26(क) के तहत किये गए अधिनियम का अनुरोध करते हुए, बीटैमेथासोन + जेटामाइसिन +
टोलनाफ्टेट + इडोक्लिरोडाइड्रोक्विनोल नामक निम्न खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ
विनिमयान, विक्रय और वितरण तत्काल प्रभाव से प्रतिपिठ रखती है।

[फा. सं. एससी-11035/53/2014-डीएफ़डीएसी]
कुंदन लाल शर्मा, संयुक्त सचिव

NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 1011(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Betamethasone + Gentamicin + Toluftate + Iodochlorhydroxyquinoline is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Betamethasone + Gentamicin + Toluftate + Iodochlorhydroxyquinoline with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

अधिसूचना

नई दिल्ली, 10 मार्च, 2016

का.श्र. 1012(अ)---केंद्रीय सरकार का यह समाधान हो गया है कि क्लोबेटासोल + जेटामाइसिन + टोलनाफ्टेट
आइडोक्लिरोडाइड्रोक्विनोल + केटोकोफानोल की नियम खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की
संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपलब्ध है;

और इस विषय के केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जोर की गई है और उक्त विशेषज्ञ समिति ने
केंद्रीय सरकार को उक्त सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय आह्वान
नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त
औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमयान, विक्रय और वितरण को प्रतिपिठ करके विनिमयित करना लोकहित में
आवश्यक और सर्वहारा है;

अतः अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन मामले
अधिनियम, 1940 (1940 का 23) की धारा 26(क) के तहत किये गए अधिनियम का अनुरोध करते हुए, क्लोबेटासोल + जेटामाइसिन +
टोलनाफ्टेट आइडोक्लिरोडाइड्रोक्विनोल + केटोकोफानोल की नियम खुराक संयोजन औषधि का मानव उपयोग के लिए
विक्रयार्थ विनिमयान, विक्रय और वितरण तत्काल प्रभाव से प्रतिपिठ रखती है।

[फा. सं. एससी-11035/53/2014-डीएफ़डीएसी]
कुंदन लाल शर्मा, संयुक्त सचिव
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1012(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Clobetasol + Gentamicin + Tolnaftate + Iodochlorhydroxyquinone + Ketoconazole is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Clobetasol + Gentamicin + Tolnaftate + Iodochlorhydroxyquinone + Ketoconazole with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1013(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Allantoin + Dimethicone + Urea + Propylene + Glycerin + Liquid Paraffin is likely to involve risk to human beings whereas safer alternatives to the said drug are available;
And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Allantoin + Dimethione + Urea + Propylene + Glycerin + Liquid Paraffin with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अधिसूचना

नई दिल्ली, 10 मार्च, 2016

का.अ. 1014(ब)—केंद्रीय सरकार का यह समाधान हो गया है कि एक्सिट्रिमाइड + थायमोल + सेटिमाइड की नियम खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपलब्ध हैं:

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विकिरणीय असर नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण को प्रतिष्ठित करके विनियमित करना लोकसहित में आवश्यक और समीचीन है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन समस्याओं बिषयन 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, एक्सिट्रिमाइड + थायमोल + सेटिमाइड की नियम खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तकनीक प्रभाव से प्रतिष्ठित करती है।

[फा. से. एस-11035/53/2014-टीएफएससी]

कंदन लाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1014(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Acriflavine + Thymol + Cetrimide is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;
Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Acriflavine + Thymol + Cetrimide with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 1015(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Betamethasone + Neomycin + Tolnaftate + Iodochlorohydroxyquinoline + Chlorocresol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Betamethasone + Neomycin + Tolnaftate + Iodochlorohydroxyquinoline + Chlorocresol with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1016(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Clobetasol + Neomycin + Miconazole + Clotrimazole is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Clobetasol + Neomycin + Miconazole + Clotrimazole with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1017(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Ketoconazole + Tea Tree oil + Allantion + Zinc Oxide + Aloe Vera + Jojoba oil + Lavender oil + Soa noodels is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Ketoconazole + Tea Tree oil + Allantion + Zinc Oxide + Aloe Vera + Jojoba oil + Lavender oil + Soa noodels with immediate effect.

[F. No. X-11035/53/2014-DFQC.]

K. L. SHARMA, Jt. Secy.
And Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Clobetasol Propionate + Ofloxacin + Ornidazole + Terbinafine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee, the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Clobetasol Propionate + Ofloxacin + Ornidazole + Terbinafine with immediate effect.

[F. No. X-11035/53/2014-DFQC.]

K. L. SHARMA, Jt. Secy.

अधिष्ठायिक

नई दिल्ली, 10 मार्च, 2016

कार्यालय 1019(व) — केंद्रीय सरकार का यह समाधन हो गया है कि क्लोबेटासोल + मियोपाइथिल + माइक्रोनाइजर + बिंक सल्फेट की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन की खतरा होने की संभावना है, जबकि उक्त औषधि के सुरुचित अनुकूल प्रयोग हैं;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय आश्वय नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधन हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण की प्रतिपाद्य पद्धति के विनियमित करना लोकहित में आवश्यक और समाजीक है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन सामग्री अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा वितरित शक्तियों का प्रयोग करते हुए, क्लोबेटासोल + मियोपाइथिल
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1019(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Clobetasol + Neomycin + Miconazole + Zinc Sulphate is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Clobetasol + Neomycin + Miconazole + Zinc Sulphate with immediate effect.

[F. No. X-11035/53/2014-DFQC.]

K. L. SHARMA, Jt. Secy.

अधिसूचना

नई दिल्ली, 10 मार्च, 2016

का.श. 1020(अ).—केंद्रीय सरकार का यह समाधान हो गया है कि बेक्लोमेशायोन ब्राय्प्रोपियोनेट + नियोमाइसिन + टोल्काफेटर + ब्रायकोलरडाइफ्रॉक्सिक्सील + क्लोरोफेलक्सील की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपयोग है;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति के केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विकृतिशील असर नहीं है;

और उक्त विशेषज्ञ समिति के सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विकृतियों विनिर्माण, विक्रय और वितरण को प्रतिपिट करके विनियमित करना लोकहित में आवश्यक और समीचीन है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रसाधन सामग्री अधिनियम, 1940 (1940 का 23) की धारा 26A के तहत प्रत्याशियों के प्रयोग करते हुए, बेक्लोमेशायोन ब्राय्प्रोपियोनेट + नियोमाइसिन + टोल्काफेटर + ब्रायकोलरडाइफ्रॉक्सिक्सील + क्लोरोफेलक्सील की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विकृतियों विनिर्माण, विक्रय और वितरण तत्काल प्रभाव से प्रतिपिपल करती है।

[फा. सं. एक्स-11035/53/2014-डीएफ़सी]
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1020(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Beclomethasone Dipropionate + Neomycin + Tolnaftate + Iodochlorhydroxyquinoline + Chlorocresol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendation of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of the fixed dose combination of Beclomethasone Dipropionate + Neomycin + Tolnaftate + Iodochlorhydroxyquinoline + Chlorocresol with immediate effect.

[F. No. X-11035/53/2014-DFQC.]

K. L. SHARMA, Jt. Secy.

अधिसूचना

नई दिल्ली, 10 मार्च, 2016

का. आ. 1021(ब)।—केंद्रीय सरकार का यह समाधान हो गया है कि बेटामेथासोन + जेंटाइमाइसिन + विंक सल्फेट + क्लोट्रोमेजोल + क्लोरोक्रेसोल का नियत भुकंत संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है; जबकि उक्त औषधि के सूचक अनुकुल उपस्थित हैं; और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जाँच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय अधिकार नहीं है; और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण को प्रतिपिप्त करके विनियमित करना लोकहित में आवश्यक और समीचीन है; अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और प्रयोग नामक अधिनियम, 1940 (1940 का 23) की धारा 26क के तहत अन्य नामक का प्रयोग करते हुए, बेटामेथासोन + जेंटाइमाइसिन + विंक सल्फेट + क्लोट्रोमेजोल + क्लोरोक्रेसोल की नियत भुकंत संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तकनीक प्रथम से प्रतिपिप्त करती है।

[फा. सं. एक्स-11035/53/2014-डीएफ़सीसी]

कुंदन लाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1020(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Betamethasone + Gentamycin + Zinc Sulphate + Clotrimazole + Chlorocresol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;
And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Betamethasone + Gentamycin + Zinc Sulphate + Clotrimazole + Chlorocresol** with immediate effect.

[F. No. X-11035/53/2014-DFQC.]

K. L. SHARMA, Jt. Secy.

**NOTIFICATION**

New Delhi, the 10th March, 2016

S.O. 1022(E).— Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Borax + Boric Acid + Naphazoline + Menthol + Camphor + Methyl Hydroxy Benzoate** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;
Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Bromhexine + Dextromethorphan with immediate effect.

[F. No. X-11035/53/2014-DFQC.]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1023(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Bromhexine + Dextromethorphan is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Bromhexine + Dextromethorphan with immediate effect.

[F. No. X-11035/53/2014-DFQC.]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1024(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Dextromethopan + Chlopheniramine + Bromhexine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Dextromethopan + Chlopheniramine + Bromhexine with immediate effect.

[F. No. X-11035/53/2014-DFQC.]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1025(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Menthol + Anesthetic Ether is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Menthol + Anesthetic Ether with immediate effect.

[F. No. X-11035/53/2014-DFQC.]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1026(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Dextromethorphan + Chlopheniramine + Ammonium + Sodium Citrate + Menthol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Dextromethorphan + Chlopheniramine + Ammonium + Sodium Citrate + Menthol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अधिसूचना

नई दिल्ली, 10 मार्च, 2016

कार्य का. 1027 (ब).— केंद्रीय सरकार का यह समाधान हो गया है कि परगोटाम डार्स्ट्रेट + बेल्लादोना शुष्क सत्व + कैफीन + पेराइस्टामोल की नियाम खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है, जबकि उक्त औषधि के सुरक्षित अनुकूल उपलब्ध है; और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विषयक समिति द्वारा जांच की गई है और उक्त विषयक समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विषमती औषधि नहीं है; और उक्त विषयक समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयवर्त विनिमय, विक्रय और वितरण का प्रतिपादन करके विविध रूप से लोकसंचार में आवश्यक और समीचीन है; अतः, अब, केंद्रीय सरकार, उक्त विषयक समिति की सिफारिशें के आधार पर और औषधि और गोधारनाम सामग्री अधिनियम, 1940 (1940 का 23) की धारा 26का द्वारा प्रदत्त शक्तियाँ का प्रयोग करते हुए, परगोटाम डार्स्ट्रेट + बेल्लादोना शुष्क सत्व + कैफीन + पेराइस्टामोल की नियाम खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयवर्त विनिमय, विक्रय और वितरण तक्ताल प्रभाव से प्रतिपादित करती है।

[फा. सं. एचस्स-11035/53/2014-कैजेस्ट्रूसी]

कुंदल लाल शर्मा, संयुक्त सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1027(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Ergotamine Tartrate + Belladona Dry Extract+Caffeine + Paracetamol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;
And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Ergotamine Tartrate + Belladona Dry Extract+Caffeine + Paracetamol with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1028(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Phenytoin + Phenobarbitone is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government
hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Phenytoin + Phenobarbitone with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1029(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Gliclazide 40mg + Metformin 400mg is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Gliclazide 40mg + Metformin 400mg with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1030(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Paracetamol + Ambroxol + Phenylephrine + Chlorpheniramine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Paracetamol + Ambroxol + Phenylephrine + Chlorpheniramine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
And Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Oflaxacin + Ornidazole Suspension is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government and the said Expert Committee recommended to the Central Government that the said drug is

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1031(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Oflaxacin + Ornidazole Suspension is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Oflaxacin + Ornidazole Suspension with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अधिसूचना

नई दिल्ली, 10 मार्च, 2016

का.अ. 1032(ब)—केंद्रीय सरकार का यह समाधान हो गया है कि एल्टेक्ट्रोल + टीरोफाइलन + ब्रोमेडेसीन + मेंथोल की नियमित बुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना है; जबकि उक्त औषधि के नुकसान अनुकूल उपलब्ध है;

और इस विषय की केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सूचना की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विकिरण जीवन को नहीं है;

और उक्त विशेषज्ञ समिति की सूचना के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण को प्रतिपिप्द करके विनियमित करना लोकप्रिय में आवश्यक और समीचीन है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सूचना के आधार पर और औषधि और प्रसाधन समिति अधिनियम, 1940 (1940 का 23) की धारा 26 के द्वारा प्रदत्त शर्तों का प्रयोग करते हुए, एल्टेक्ट्रोल + टीरोफाइलन + ब्रोमेडेसीन + मेंथोल की नियमित बुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तक्कल प्रभाव से प्रतिपिप्द करती है।

[फा. मं. एस.सी-11035/53/2014-डीएफीसी]

कुंदन लाल शर्मा, संयुक्त सचिव
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1032(E).— Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Albuterol + Etofylline + Bromhexine + Menthol** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of the said drug **fixed dose combination of Albuterol + Etofylline + Bromhexine + Menthol** with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

बाध्यसूचना

नई दिल्ली, 10 मार्च, 2016

कार्य. 1033(अ).— अनुच्छेद 26A** के** अधीन सरकार का यह समाधान हो गया है कि एलब्युटेरोल + थ्रोम्हेक्सीन + थियोफाइलिन की नियमित खुराक संयोजन औषधि के प्रयोग से मानव जीवन को खतरा होने की संभावना हैं, जबकि उक्त औषधि के सुरक्षित अनुकूल्य उपलब्ध हैं;

और इस विषय के केंद्रीय सरकार द्वारा नियुक्त विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सिफारिश की है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई विकिरणीय औषध्य नहीं है;

और उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रय विनिमय, विक्रय और वितरण की प्रतिपादित कर्म विनियमित करना लोकतान्त्रिक और आचार्यकृति और माध्यमिक हैं;

अत: अन्तः, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सिफारिशों के आधार पर और औषधि और नामीराज समूह अधिनियम, 1940 (1940 का 23) के धारा 26 के अनुसार प्रतल्य शक्तियों का प्रयोग करते हुए, एलब्युटेरोल + थ्रोम्हेक्सीन + थियोफाइलिन की नियमित खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रय विनिमय, विक्रय और वितरण तत्काल प्रभाव से प्रतिपादित करती हैं।

[फा. स. एस-11035/53/2014-दीएफएससी]
कुंदन लाल शर्मा, मुख्य सचिव

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1033(E).— Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Albuterol + Bromhexine + Theophylline** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;
And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Albuterol + Bromhexine + Theophylline with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1034(E).— Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Salbutamol+Hydroxyethyltheophylline (Etofylline) + Bromhexine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Salbutamol+Hydroxyethyltheophylline (Etofylline) + Bromhexine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
And Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Paracetamol+Phenylephrine+Levocetirizine+Sodium Citrate is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Paracetamol+Phenylephrine+Levocetirizine+Sodium Citrate with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of the said drug fixed dose combination of Paracetamol + Propyphenazone + Caffeine with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 1037(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Guaifenesin + Diphenhydramine + Bromhexine + Phenylephrine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Guaifenesin + Diphenhydramine + Bromhexine + Phenylephrine with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

NOTIFICATION
New Delhi, the 10th March, 2016

S.O. 1038(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Dried Aluminium Hydroxie Gel + Propantheline + Diazepam is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;
And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Dried Aluminium Hydroxide Gel + Propantheline + Diazepam with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1039(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Bromhexine + Phenylephrine + Chlorpheniramine + Paracetamol is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Bromhexine + Phenylephrine + Chlorpheniramine + Paracetamol with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1040(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Beclomethasone + Clotrimazole + Gentamicin + Iodochlorhydroxyquinoline is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Beclomethasone + Clotrimazole + Gentamicin + Iodochlorhydroxyquinoline with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1041(E).—Whereas, the Central Government is satisfied that the use of the drug **fixed dose combination of Telmisartan + Metformin** is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug **fixed dose combination of Telmisartan + Metformin** with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

अधिसूचना

इस दिनिन्द्र, 10 मार्च, 2016

का. आ. 1042(अ).—केंद्रीय सरकार का यह समाधान हो गया है कि **भमोनियम साइट्रेट + विक्टीम बी12 + फोलिक एसिड + बिक्स सल्फेट** की नियत खुराक संयोजन औषधि के प्रयोग से मानव जीवन की खतरा होने की संभावना है, जबकि उक्त औषधि के नुकसान अनुकूल उपत्यका हैं;

और इस विषय की केंद्रीय सरकार द्वारा सिपाहु विशेषज्ञ समिति द्वारा जांच की गई है और उक्त विशेषज्ञ समिति ने केंद्रीय सरकार को यह सूचना दी है कि उक्त औषधि के बारे में यह पाया गया है कि इसका कोई चिकित्सीय आश्चर्य नहीं है;

और उक्त विशेषज्ञ समिति की सूचना के आधार पर केंद्रीय सरकार का यह समाधान हो गया है कि देश में उक्त औषधि के मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण को प्रतिपिद्ध करके विनियमित करना लोकहित में आवश्यक और सामीच्छिक है;

अतः, अब, केंद्रीय सरकार, उक्त विशेषज्ञ समिति की सूचना के आधार पर और औषधि और प्रामाण्य सामग्री अधिनियम, 1940 (1940 का 23) की धारा 26क द्वारा प्रदत्त शर्तें का प्रयोग करते हुए, **भमोनियम साइट्रेट + विक्टीम बी12 + फोलिक एसिड + बिक्स सल्फेट** की नियत खुराक संयोजन औषधि का मानव उपयोग के लिए विक्रयार्थ विनिमय, विक्रय और वितरण तकाल प्रभाव में प्रतिपिद्ध करती है।
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1042(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Ammonium Citrate + Vitamin B 12 + Folic Acid + Zinc Sulphate is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Ammonium Citrate + Vitamin B 12 + Folic Acid + Zinc Sulphate with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1043(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Levothyroxine + Phyridoxine + Nicotinamide is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;
And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Levothyroxine + Phyridoxine + Nicotinamide with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.

NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1044(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Benfotiamine + Metformin is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Benfotiamine + Metformin with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1045(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Thyroid + Thiamine + Riboflavin + Pyridoxine + Calcium Pantothenate + Tocopheryl Acetate + Nicotinamide is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Thyroid + Thiamine + Riboflavin + Pyridoxine + Calcium Pantothenate + Tocopheryl Acetate + Nicotinamide with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1046(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Ascorbic Acid + Manadione Sodium Bisulphate + Rutin + Dibasic Calcium Phosphate + Adrenochrome mono Semicarbazone is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Ascorbic Acid + Manadione Sodium Bisulphate + Rutin + Dibasic Calcium Phosphate + Adrenochrome mono Semicarbazone with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1047(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Phenylephrine + Chlorpheniramine + Paracetamol + Bromhexine + Caffeine is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Phenylephrine + Chlorpheniramine + Paracetamol + Bromhexine + Caffeine with immediate effect.

[F. No. X-11035/53/2014-DFQC]
K. L. SHARMA, Jt. Secy.
NOTIFICATION

New Delhi, the 10th March, 2016

S.O. 1048(E).—Whereas, the Central Government is satisfied that the use of the drug fixed dose combination of Clotrimazole + Beclomethasone + Lignocaine + Ofloxacin + Acetic Acid + Sodium Methyl Paraben + Propyl Paraben is likely to involve risk to human beings whereas safer alternatives to the said drug are available;

And Whereas, the matter has been examined by an Expert Committee appointed by the Central Government and the said Expert Committee recommended to the Central Government that the said drug is found to have no therapeutic justification;

And Whereas on the basis of the recommendations of the said Expert Committee, the Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of the said drug in the country;

Now, therefore, on the basis of the recommendations of the said Expert Committee and in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby prohibits the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Clotrimazole + Beclomethasone + Lignocaine + Ofloxacin + Acetic Acid + Sodium Methyl Paraben + Propyl Paraben with immediate effect.

[F. No. X-11035/53/2014-DFQC]

K. L. SHARMA, Jt. Secy.